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TIIVISTELMÄ 
Eturauhassyöpä on miesten yleisin syöpä länsimaissa. Syövän vaarallisuuden määrää suurelta osin 
sen kyky tunkeutua ympäröivään kudokseen ja lähettää etäispesäkkeitä. Eturauhassyövän 
leviämiseen ja metastaasiin johtavat molekulaariset mekanismit tunnetaan kuitenkin yhä suurelta osin 
heikosti. Nämä mekanismit täytyy tuntea, jotta voidaan löytää uusia apuvälineitä eturauhassyövän 
diagnosointiin ja tarkemman ennusteen tekemiseen sekä suunnitella parempia terapioita syövän 
leviämisen pysäyttämiseksi. 
 
Tässä työssä tutkittiin pitkälle edenneessä syövässä yli-ilmentyvän androgeenireseptorin säätelemän 
mikroRNA:n, miR-32:n, vaikutusta peptidaasi-inhibiittori 15:n (PI15) ilmentymiseen 
eturauhassyövän solulinjoissa PC-3 ja LNCaP. Tämä miRNA–kohdegeeni-pari herätti kiinnostuksen, 
sillä kastraatioresistentit syövät ovat tyypillisesti hyvin aggressiivisia ja peptidaaseilla ja 
proteaaseilla, joita PI15 inhiboi, on tähän suuri vaikutus. Hypoteesina on, että pitkälle edenneessä 
syövässä miR-32 vaimentaa PI15:n ilmentymisen, jolloin peptidaasien toiminta on aktiivisempaa ja 
syövän leviäminen kiihtynyttä.  
 
Edellä mainittuja solulinjoja transfektoitiin PI15 geenin sisältävällä plasmidilla saman aikaisesti pre-
miR-32:lla ja vaikutuksia PI15:n ilmentymiseen mitattiin qRT-PCR:lla ja western blot-menetelmällä. 
Lisäksi tehtiin reportterivektori, jossa lusiferaasi-geeni kytkettiin PI15:n 3’ säätelyalueeseen, jolloin 
voidaan mitata miR-32:n säätelyvaikutusta lusiferaasin ilmentymiseen suoraan proteiinitasolla. Myös 
PI15:n yli-ilmentämisen vaikutuksia tutkittiin kloonaamalla PI15 geenin koodaava alue uuteen 
plasmidiin, jossa on nisäkässoluissa toimiva selektiogeeni, ja transfektoimalla PC-3 solulinja 
pysyvästi hyödyntäen antibiootin aikaan saamaa selektiopainetta. Näin saatujen PI15:ttä stabiilisti 
yli-ilmentävien PC-3 kloonien kasvunopeutta ja solujen elinkelpoisuutta mitattiin verrattuna tyhjällä 
plasmidilla transfektoituihin klooneihin. 
 
PI15:n ja miR-32:n yhtäaikaisen transfektion aiheuttama hajonta osoittautui liian suureksi pitävien 
johtopäätösten tekemiseksi miR-32:n vaikutuksesta PI15:n ilmentymiseen. Tulevaisuudessa tehtävä 
lusiferaasi-reportterikoe voisi vastata paremmin tähän kysymykseen. PI15:n ilmentymistä ei tämän 
työn puitteissa kyetty todentamaan proteiinitasolla. Geenin yli-ilmentäminen kuitenkin johti selvästi 
alentuneeseen kasvunopeuteen ja solujen elinkelpoisuuteen sekä fenotyypin muuttumiseen 
suurimmalla ilmentämisen tasolla. Jatkotutkimusta vaaditaan, jotta voidaan osoittaa PI15 proteiinin 
aikaan saavan nämä muutokset. 
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ABSTRACT 
Prostate cancer is the most common cancer in men in western countries. The most dangerous property 
of cancer is the ability to spread into the surrounding tissue and to metastasize. The molecular 
mechanisms underlying these processes are still poorly understood in prostate cancer. These 
mechanisms must be studied more deeply in order to find new tools for prostate cancer diagnostics 
and prognostics as well as to design better therapies to tackle the disease. 
 
In this work we studied the effects of miR-32 on the expression of peptidase inhibitor 15 (PI15) in 
prostate cancer cell lines PC-3 and LNCaP. MiR-32 is an androgen receptor regulated microRNA 
that is overexpressed in castration resistant prostate cancer. Interest in this miRNA–target pair arouse 
because the castration resistant disease is aggressive and peptidases and proteases that PI15 inhibits 
have great influence on this matter. The hypothesis is that miR-32 downregulates PI15 expression 
leading to increased peptidase activity and enhanced invasion of cancer cells. 
 
The aforementioned cell lines were transfected with PI15 vector concomitantly with miR-32 and the 
effects on PI15 expression were observed by qRT-PCR and western blot. In addition, we constructed 
a luciferase reporter vector with luciferase gene integrated to PI15 3’ UTR. In this vector, expression 
of luciferase is regulated by miRNAs that can bind to the 3’ UTR. Finally, the effects of PI15 
overexpression were studied by cloning PI15 open reading frame into a vector with a mammalian 
selection marker and then transfecting this vector stably into PC-3 cell line with the help of antibiotic 
selection. These stably PI15 overexpressing cells were used to measure growth speed and cell 
viability in comparison to cells transfected with an empty plasmid. 
 
The dispersion of co-transfection of PI15 and miR-32 turned out to be too high to draw conclusions 
of whether miR-32 affects PI15 expression or not. The luciferase reporter assay might give firmer 
answers for this matter and remains a subject of future work. Unfortunately, we could not detect PI15 
in the protein level. Nevertheless, the overexpression of PI15 significantly reduced growth and 
viability of the stable clones and changed the cell phenotype in the highest level of overexpression. 
Further research is needed to confirm that it is the PI15 protein that causes these changes. 
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SNP single nucleotide polymorphism 
SPINK1 serine peptidase inhibitor, Kazal type 1 
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TARBP2 RISC loading complex RNA binding subunit 
TCGA the cancer genome atlas research network 
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TOP2B topoisomerase (DNA) II beta 
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TP53 tumor protein 53 
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1. INTRODUCTION 
Prostate cancer is the most common cancer in European men with approximately 417 100 new cases 
diagnosed in 2012 (Ferlay, Soerjomataram et al. 2015). It is also the third most common cause of 
cancer deaths (Ferlay, Soerjomataram et al. 2015). The inconsistency between incidence and 
mortality has been established during last two decades as a result of serum based test for prostate 
specific antigen (PSA) (Ferlay, Soerjomataram et al. 2015, Prensner, Rubin et al. 2012). Detection of 
elevated levels of this biomarker has allowed early detection of prostate cancers overall but 
identification of the high risk patients with potential to an aggressive disease remains a major clinical 
challenge (Shen, Abate-Shen 2010). 
 
It is the aggressive form of the disease that would deserve better treatment solutions, as it is the main 
cause of death by prostate cancer. Currently, androgen deprivation therapy is still the best available 
treatment for locally advanced or metastatic prostate cancer, but despite the promising response 
during the early phase of the treatment, the disease almost invariably gains resistance and the resulting 
castration resistant prostate cancer (CRPC) is incurable (Shen, Abate-Shen 2010). 
 
Overcoming these challenges requires thorough understanding of the molecular mechanisms 
underlying the biology of prostate cancer. One of such mechanisms is post-transcriptional microRNA 
mediated gene silencing (Jonas and Izaurralde 2015). Multiple studies have established dysregulation 
miRNA expression during prostate cancer carcinogenesis (Lu et al. 2005, Volinia et al. 2006, Porkka 
et al. 2007, Ambs et al. 2008, Ozen et al. 2008, Schaefer et al. 2010).  
 
One of such potentially carcinogenesis driving miRNAs is miR-32. Its expression is regulated by the 
androgen receptor and it has been shown to be overexpressed in CRPC compared with benign 
prostatic hyperplasia (BPH) (Jalava et al. 2012). MiR-32 has also been shown to downregulate tumor 
protein p53 effector gene BTG2 both in vitro and in vivo (Jalava et al. 2012) and BCL2L11 encoding 
apoptotic regulator bcl-2-like protein 11 in vitro (Ambs et al. 2008).  To further validate miR-32’s 
connection to carcinogenesis, more target genes are being searched. The present study was motivated 
by the prediction of microRNA.org target prediction program (Betel et al. 2008 and 2010) that miR-
32 has a potential binding site in the 3’UTR region of peptidase inhibitor 15 (PI15) mRNA. Early 
results from murine model studies have shown that expression of PI15 mRNA is indeed lower in 
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miR-32 overexpressing mice in comparison to wild type mice. Similar results were acquired in AR 
positive PCa cell line 22Rv1. 
 
The functional role of PI15 as an extracellular peptidase inhibitor makes it an interesting possible 
target for miR-32: If it is downregulated by miR-32 that has been associated with more aggressive 
disease, it would provide one possible explanation of why CRPC is more invasive, as the absence of 
peptidase inhibitor would lead to higher activity of proteases and increased proteolysis in the tissue. 
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2. REVIEW OF THE LITERATURE 
2.1 MicroRNAs  
MicroRNAs are short ~18–24 nucleotide long RNA species that target mRNAs usually decreasing 
their expression at the post-transcriptional level. They are well conserved in evolution from nematode 
to mammals, which highlights their importance in the control of gene expression. There are almost 
1900 putative miRNA genes in the human genome (http://www.mirbase.org; 19.2.2016, Kozomara 
et al. 2011), although probably not all of them are genuine.  Nevertheless, based on the sequence, 
they can bind to most of the protein coding genes (Friedman et al. 2009) having the potential to 
control their expression.  This is possible because many miRNAs can bind multiple different target 
mRNAs. Furthermore, several miRNAs can bind the same target mRNA making the network of 
miRNA mediated modulation even more diverse. From this context it is not surprising that miRNAs 
have been shown to participate in the regulation of many cellular processes that are disrupted during 
carcinogenesis including control of proliferation, differentiation and apoptosis (Kloosterman & 
Plasterk 2006). 
 
Most miRNAs are transcribed by RNA polymerase II and 5’-capped and polyadenylated just like 
mRNAs (Lee et al. 2004). The pri-miRNA transcripts are then cut into shorter hairpin shaped pre-
miRNA precursors in the nucleus by the microprocessor complex constituting of ribonuclease 3 
(DROSHA) and DiGeorge syndrome critical region 8 (DGCR8) proteins (Gregory et al. 2004). After 
export to the cytoplasm by exportin 5 (Yi et al. 2003), the pre-miRNA is subject to further processing 
by endoribonuclease Dicer, which cleaves the pre-miRNA into mature ~22 nucleotide miRNA 
duplexes (Bernstein et al. 2001).  
 
The miRNA induced gene silencing complex (miRISC), which is responsible of the actual effects of 
the silencing mechanism, is assembled directly after the last cleavage step. RISC-loading complex 
subunit TARBP2 that accompanies Dicer in the last cleavage step guides the miRNA duplex to the 
protein argonaute 2 (AGO2) (Chendrimada et al. 2005), which is essential for the catalytic activity of 
the silencing complex in mammals (Liu et al. 2004). In addition to AGO2, the miRISC includes 
GW182 family proteins, which guide the silencing complex into P-bodies where the miRNA 
mediated gene silencing takes place (Liu et al. 2005a). The miRNA biogenesis is summarized in 
Figure 1. 
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Figure 1. Canonical miRNA biogenesis pathway. Pri-miRNAs are transcripted by RNA polymerase II, and 
digested by microprocessor complex in the nucleus. After export to cytoplasm through exporting 5, pre-
miRNAs are further cleaved by the DICER. The miRNA duplex is next separated and one of mature miRNAs 
is loaded into the RISC complex that mediates RNA interference. See further discussion in the text. Figure 
adapted from Lin and Gregory 2015. 
 
In order to bind to its target mRNA, the miRNA guide has to be separated from the complementary 
passenger strand. The mechanism of this process is still unclear, although slicing of the passenger 
strand or a passive mismatch driven process have been suggested (Czech & Hannon 2011).   
 
The mature RISC complex silences mRNAs complementary to the miRNA in organelles called p-
bodies (Liu et al. 2005a, Liu et al. 2005b). The fate of mRNA is dependent on the degree of 
complementarity of miRNA to its target sequence: In mammals, miRNAs are rarely completely 
complementary to the mRNA, a case that leads to direct cleavage of the mRNA by AGO2 (Liu et al. 
2004), but contain several mismatched nucleotides, which leads to other ways of downregulation of 
the target translation. The major mechanisms for downregulation of the target expression seems to be 
accelerated mRNA decay by deadenylation and decapping of mRNAs RISC dependently (Guo et al. 
2010, Eichhorn et al. 2014). It appears to be directly connected to the common mRNA decay pathway 
responsible for mRNA turnover (Guo et al. 2010, Eichhorn et al. 2014).  
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Also other mechanisms by which miRNAs mediate regulation of gene expression exist. For example, 
some mRNAs are held in repressed but stable state for later use in translation, allowing rapid 
translational response to environmental signal (Muddasheddy et al. 2011). Additionally, in specific 
occasions, typically during cell cycle arrest, some miRNAs can function as translation activators 
(Vasudevan et al. 2007). In both cases these phenomena require specific accessory proteins that bind 
to AGO2 in order to change the basic behavior of the RISC complex (Muddasheddy et al. 2011, 
Vasudevan et al. 2007). 
 
2.2 Prostate gland 
Prostate is a walnut sized organ residing just under the bladder. It is part of the male reproduction 
system and its main function is to produce secretions to the seminal fluid. Generally accepted 
anatomical model of the prostate divides the organ into four zones. Three of these zones are glandular 
and possess ductal anatomy whereas the remaining zone is mainly connective tissue and smooth 
muscle (McNeal 1981).  
 
The glandular zones are named peripheral, central and transition zones. Central zone is different from 
the other two deriving from Wolffian duct, whereas the other two derive from the urogenital sinus 
(McNeal 1981). Histologically the central zone has denser acini and ducts (McNeal 1981, Virtanen, 
Hervonen 1995). The Peripheral zone is under the other two and constitutes ~70 % of the mass of 
prostate (McNeal 1981). The structure of the acini and ducts in the peripheral zone is less dense and 
simpler than in the central zone (Virtanen & Hervonen 1995, Laczkó et al. 2005). The transition zone 
has also smaller ducts and it is mainly distinguished from peripheral zone by being in the closer 
proximity to uretha between central zone and periurethal smooth muscle sphincter (McNeal 1981, 
Virtanen & Hervonen 1995).  Benign prostatic hyperplasia (BPH) is developed almost exclusively in 
the transition zone, whereas most of the carcinomas arise in the peripheral zone (McNeal 1981). It 
has been proposed that the reason for higher rate of cancer incidence in the peripheral zone is due to 
higher rates of cellular proliferation in the zone (Laczkó et al. 2005). This notion is in accordance 
with the recent report stating that cancer risk in variety of other tissue types is attributable solely to 
their rate of stem cell division (Tomasetti & Vogelstein 2015). 
  
The glandular epithelium of the prostate is pseudostratified. High columnar luminal cells are the most 
abundant cell type covering the lumen of the acini and ducts and are responsible for the prostate’s 
6 
 
secretion (van Leenders & Schalken 2003). In addition to them there are basal cells, which are 
believed to be the stem cells for the luminal cells (van Leenders & Schalken 2003). Much rarer are 
the neuroendocrine cells that grow in small clusters and whose biological role in the prostate is still 
under debate, but they may be involved in regulation of exocrine cells in the prostate stroma (van 
Leenders & Schalken 2003). The prostate epithelium exchanges paracrine signals with urogenital 
mesenchyme during and after the prostate development (Shen & Abate-Shen 2010, van Leenders & 
Schalken 2003). Most of the prostate carcinomas are of the luminal phenotype (prostate acinar 
adenocarcinoma), but a rare and aggressive type is initiated from the neuroendocrine cells (prostate 
small cell carcinoma) (Shen, Abate-Shen 2010). From here on the discussion of prostate carcinoma 
will refer to the adenomatous type, if not otherwise mentioned. 
 
2.3 Prostate carcinoma 
2.3.1 Epidemiological factors 
Prostate cancer is the second most common cancer in men globally and the most common cancer in 
European men (Ferlay et al. 2015). However, it is only the fifth leading cause of cancer mortality in 
men worldwide and the third in Europe (Ferlay et al. 2015). This gap between incidence and mortality 
rates is due to indolent nature of many prostate cancers. In addition, prostate cancer is frequently 
diagnosed at old age (Grönberg 2003), which raises the probability that the patient dies of other 
causes. 
 
During the last few decades, prostate cancer incidence has been increasing around the world (Zhou 
et al. 2016). This is attributable to more sensitive detection of the existing cases rather than vast 
increases of the actual cancer incidence (Zhou et al. 2016). Especially the introduction of blood based 
screening for prostate cancer with prostate specific antigen (PSA) has led to early detection of the 
disease even in asymptomatic men (Prensner et al. 2012). This has not been completely unproblematic 
though, as will be discussed later.  
 
In addition to age, the most important unmodifiable risk factors for prostate cancer are ethnic 
background and positive family history of the disease (Cuzick et al. 2014). For instance, the disease 
is more common in American men with African ancestry than in white non-Hispanic males in the 
USA (Merrill & Sloan 2012). Lifetime risk for white men is 15,7 % whereas for black men it is 18,5 
%  (Merrill & Sloan 2012). In contrast, for men with Asian origin the risk for prostate cancer specific 
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mortality is generally lower than in white non-Hispanic males (Chao et al. 2015). The higher 
incidence in African Americans has been attributed to more frequent genetic alterations in the 
susceptibility locus 8q24 (Gudmundsson et al. 2007). 
 
In a large Nordic twin study (Lichtenstein et al. 2000) hereditability of prostate cancer was estimated 
to be as much as 42 % in Scandinavian population. However, known high risk mutations can explain 
only a mere fraction of prostate cancer hereditability (Attard et al. 2016). Genome wide association 
studies have greatly enhanced detection sensitivity over linkage mapping (Eeles et al. 2014), which 
has allowed to detect a total of 77 mostly low risk cancer susceptibility alleles (Attard et al. 2016). 
Indeed, most of the known prostate cancer susceptibility alleles are common, low penetrance single 
nucleotide polymorphisms (SNPs) that reside in intergenic or intronic regions and act synergistically 
(Eeles et al. 2014).  
 
To date, non-synonymous germline mutations in several genes have been linked to predisposition to 
prostate cancer. One of these genes, HOXB13, has been linked to earlier onset of prostate cancer with 
odds ratio of 2,93; although it’s mechanism of action and remains elusive (Ewing et al. 2012, Kote-
Jarai et al. 2015). Clinical relevance of HOXB13 (G84E) is limited to possible screening of members 
of carrier families as its effects on cancer progression, aside from earlier onset, or treatment outcomes 
have not been identified (Kote-Jarai et al. 2015). 
 
In addition, mutations in several DNA damage repair genes have been linked to early onset and 
aggressive phenotype of prostate cancer (Attard et al. 2016). The most important of these is BRCA2, 
a double strand break repair gene that was first identified as a cause for familial breast and ovarian 
cancers (Breast Cancer Linkage Consortium 1999). In heterozygous carriers, deleterious mutations 
have been attributed to almost five-fold lifetime risk to prostate cancer (Breast Cancer Linkage 
Consortium 1999) and 8,6-fold increase in early (< 65 years of age) onset disease (Kote-Jarai et al. 
2011a). Also the prognosis for BRCA2 mutation carriers is poorer than to unaffected individuals as 
the clinical progression in the mutation carriers is faster (Kote-Jarai et al. 2011a). 
 
There are also some rare germline variants of genes that are most frequently altered in sporadic 
prostate cancer. For example, Xq12 containing proto-oncogene AR has been identified as one possible 
susceptibility locus, although the changes do not affect coding region (Kote-Jarai et al. 2011b). Also 
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the susceptibility alleles in the aforementioned locus 8q24 have been shown to function as cell type 
specific enhancers for proto-oncogene MYC in vitro (Ahmadiyeh et al. 2010). In addition, germline 
variants altering the expression of PSA encoding gene KLK3 and other kallikrein family genes have 
been found (Cramer et al. 2003, Kote-Jarai et al. 2011c). However, their association to risk of prostate 
cancer is not clear (Kote-Jarai et al. 2011c). All in all, the identified changes in these genes are quite 
minute, which can be explained by their vital roles in cellular activities. Major changes especially in 
genes that encode proteins that function in key pathways, would most probably be lethal already in 
early stages of embryonic development. 
 
Although the knowledge of identified germline alterations explains about 35 % of the estimated 
prostate cancer hereditability, it leaves majority of the genetic susceptibility factors uncharacterized 
(Attard et al. 2016). It is probable that the interactions of the yet unidentified germline alterations 
constitute of number of alleles with complex interactions (Eeles et al. 2014).  
 
Besides genetics, there is evidence of causality between lifestyle related risk factors such as smoking 
(Zu & Giovannucci 2009) and obesity (Buschemeyer & Freedland 2007) and higher incidence or 
poorer prognosis of prostate cancer. 
 
2.3.2 Prostate cancer genetics 
Prostate cancer is a heterogeneous malignancy that arises from mostly somatic changes in the genome 
of prostate epithelial cells. Traditionally changes altering function of two classes of genes have been 
sought-after. These two classes of driver genes include tumor suppressors that act as a barrier for 
uncontrollable growth, proliferation and migration, and proto-oncogenes that are commonly 
activators of pathways associated with these functions.  
 
Tumor suppressors are affected by loss-of-function type of alterations, which can be caused by 
structure altering or expression decreasing substitutions, insertions, deletions or epigenetic changes. 
Tumor suppressors often require inactivation of both alleles to affect tumorigenesis. This is generally 
known as “two hit hypothesis” (Knudson 1971). Although in some instances loss of one allele 
decreases the gene dosage sufficiently to induce tumorigenicity.  
 
9 
 
Proto-oncogenes, on the other hand, are subject to activating events, often mutation or genomic 
rearrangement that either cause gain-of-function type of change, for example making them 
constitutively active or altering their substrate specificity. Often simple overexpression is enough to 
convert proto-oncogene into an active oncogene that is irresponsive to regulatory signals. 
 
The knowledge of genomic alterations in prostate cancer has been vastly increasing since the 
establishment of high-throughput sequencing methods. The mutations vary from SNPs and other 
small insertions and deletions to copy number alterations (CNAs) of whole chromosomes (Taylor et 
al. 2010, Robinson et al. 2015). CNAs have been implicated to have more effect on PCa progression 
than point mutations (Taylor et al. 2010, Berger et al. 2011, Grasso et al. 2012, Baca et al. 2013, The 
Cancer Genome Atlas Research Network (TCGA) 2015). They even seem to occur in a chain like 
and coordinated manner (Baca et al 2013, Berger et al. 2011). The amount of point mutations varies 
from similar to lower (Vogelstein et al. 2013, TCGA 2015, Berger et al. 2011, Taylor et al. 2010) in 
comparison to other solid tumors, but increases with patient age and disease progression (TCGA 
2015).  
 
Relatively few recurrent mutations that affect specific proto-oncogenes and tumor suppressors are 
known in PCa (Taylor et al. 2010). Recently, the cancer genome atlas research network reported that 
many primary tumors can be classified to seven distinct subgroups according to the driver genes that 
are mutated (TCGA 2015). However, one fourth of the analyzed 333 tumors could not be assigned to 
any of these subclasses (TCGA 2015), highlighting the heterogeneity of the disease. Despite of this 
large group of unclassifiable cases, most PCas have mutations in certain key pathways (Taylor et al. 
2010, Barbieri et al. 2013).  
 
2.3.2.1 Key signaling pathways in PCa carcinogenesis 
PI3K pathway is among the most frequently altered in cancer genomes. Defects in both tumor 
suppressor functions and proto-oncogenes have been reported on this pathway in PCa (Barbieri et al. 
2013).  PI3K signaling initiates from the cell membrane where the enzyme after which the pathway 
is named phosphoinositide-3-kinase (PI3K) is activated by membrane bound receptor tyrosine 
kinases following extracellular growth signal (Courtney et al. 2010). PI3K phosphorylates the sugar 
group of phosphatidylinositol glycolipid creating binding platform for v-akt murine thymoma viral 
oncogene homolog 1 or AKT1 (encoded by AKT1) (Courtney et al. 2010). After binding, AKT1 is 
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also phosphorylated and becomes active (Courtney et al. 2010). It has multiple cellular targets and its 
activation eventually leads to functions that are inherently related to the cancer phenotype, namely: 
growth, proliferation and antiapoptotic and pro-survival signaling (Courtney et al 2010).  
 
Phosphatase and tensin homolog (PTEN) acts as the most important gatekeeper of the pathway by 
dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate and thereby obstructing AKT1 
activation (Courtney et al. 2010). It is also one of the most frequently deleted genes in prostate cancer 
(Taylor et al. 2010, Barbieri et al. 2012, Robinson et al. 2015). In addition, PHLPP1, a phosphatase 
that deactivates AKT, has also been found to be recurrently altered in both primary and metastatic 
PCa (Taylor et al 2010, Chen et al. 2011). Moreover, deletion of both PTEN and PHLPP1 are more 
frequent in metastatic prostate cancer carrying TP53 deletion or mutation, suggesting that the p53 
acts as a barrier against mutations of both PTEN and PHLPP1 or 2, although the exact order of these 
events is not clear (Chen et al. 2011). 
 
Amplification of kinases in the upstream of the pathway, especially PI3KCA, is also a common 
mechanism for PI3K pathway hyperactivity in PCa (Barbieri et al . 2013). By contrast AKT1 
mutations are quite rare, as only about 1,4 % of PCas have been estimated to have the activating E17K 
mutation (Boormans et al. 2010). Finally, in the downstream of the PI3K signaling pathway another 
tumor suppressor, CDKNB1, cyclin-dependent kinase inhibitor 1B an important regulator of cell cycle 
progression, is among recurrently deleted loqi in PCa (Lapointe et al. 2007, Taylor et al. 2010, 
Barbieri et al. 2013). 
 
From the clinical point of view, the most important signal system in prostate cancer is the AR 
signaling pathway, because it is frequently targeted with androgen deprivation therapy (ADT) as a 
treatment. AR is a nuclear receptor expressed by prostate luminal and stromal cells but not by the 
neuroendocrine cells and generally not by the basal cells (Zhou et al. 2015). It is activated by androgen 
hormones such as testosterone causing AR binding to DNA and transcriptional activation of target 
genes (Shen & Abate-Shen 2010, Zhou et al. 2015). In the normal prostate, AR signaling is complex 
interplay between stromal and epithelial cells and involves several binding partners of AR that can 
modulate its functions from a cell type to another (Shen & Abate-Shen 2010, Zhou et al. 2015). This 
complex network still remains incompletely understood, but the key functions are related to keeping 
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tissue homeostasis by supporting differentiation of luminal cells and promoting their survival while 
keeping the self-renewal of the epithelium in balance (Zhou et al. 2015). 
 
Alterations in AR gene occur only after ADT (Visakorpi et al. 1995, Linja & Visakorpi 2004, Taylor 
et al. 2010). This suggests that AR itself does not initially drive carcinogenesis. However, it is 
required for the survival of prostate cancer cells and gain-of-function mutations become survival 
advantage when the selection pressure of the treatment forces to survive with minimal androgens 
(Barbieri et al. 2013). AR signaling may, however, play a role in early carcinogenesis via AR binding 
partners some of which have been found recurrently mutated in both primary and metastatic CRPCs. 
These genes include transcription factors forkhead box A1, FOXA1 that modulates AR regulated 
transcription (Gao et al. 2003, Barbieri et al. 2012, Grasso et al. 2012) and nuclear receptor coactivator 
2, NCOA2, which is after its name coactivator of AR (Taylor et al. 2010). 
 
2.3.2.2 Other common somatic alterations in PCa carsinogenesis 
The most usual genetic rearrangement in PCa identified by Tomlins et al. in 2005 is TMPRSS2–ERG 
gene fusion, in which the promoter of AR regulated gene TMPRSS2 is fused with the coding region 
of transcriptional regulator ERG (Tomlins et al. 2005, Rubin et al. 2011). There are also other AR 
regulated 5’ fusion partners and ETS transcription factor family members that are alternative to 
TMPRSS2–ERG fusion (Rubin et al. 2011). Jointly they are present in 50 to 70 % of PCas (Rubin et 
al. 2011). Because of high prevalence of ETS gene fusions and their molecular and phenotypic profiles 
it has become widely accepted that they form at least one distinct clinical entity (Rubin et al. 2011, 
TCGA 2015). 
 
The commonness of seemingly such an improbable event is due to the growth benefit posed by the 
fusion as well as the mechanism that drives the gene fusion. ETS gene fusions do not occur in random. 
Instead, they seem to be guided by androgen receptor binding (Lin et al. 2009, Haffner et al. 2010). 
DNA topoisomerase TOP2B (Haffner et al. 2010) or other enzymes in the conditions of genotoxic 
stress (caused by exogenous agents such as radiation) can generate double strand breaks (DSBs) that 
can act as recombination sites (Lin et al. 2009). The probability of successful recombination during 
non-homologous end joining is increased by co-localization of androgen induced TMPRSS2, and ERG 
during androgen stimulation (Lin et al. 2009).  
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The oncogenic action of ERG has been attributed to higher activity of serine proteases (Klezovitch et 
al. 2008). This causes disruption of the basal membrane and formation of prostate intraepithelial 
neoplasia (PIN, discussed in section 2.3.3) in mice (Klezovitch et al. 2008). Although causing more 
invasive phenotype (Klezovitch et al. 2008), ERG overexpression does not lead to cancer progression 
without further lesions in genes such as PTEN of which deletion is enriched in TMPRSS2–ERG fusion 
positive cancer (King et al. 2009, Taylor et al. 2010, TCGA 2015). Together with heterogeneous loss 
of Pten, ERG overexpression was shown to cause rapid progression with increased proliferation and 
migration of PCa in mouse studies (Carver et al. 2009). 
 
TMPRSS2–ERG fusion positive PCas also have higher occurrence of TP53 deletions (Taylor et al. 
2010). Cellular tumor antigen p53 encoded by TP53 is a key tumor suppressor that regulates response 
to diverse stress situations eventually leading to DNA damage repair, cellular senescence or 
apoptosis. Traditionally loss of p53 function has been seen as a late event in carcinogenesis but it 
occurs also in primary PCa (Taylor et al. 2010), although nowhere near as frequently as in CRPC 
where it is prevalent in over 50 % of cases (Robinson et al. 2015).  
 
Subset of ETS fusion negative cancers has been found to have recurrent mutations in SPOP (speckle 
type BTB/POZ protein) (Barbieri et al. 2012). Speckle-type POZ protein is the substrate binding 
subunit of Cullin based E3 ubiquitin ligase that regulates target proteins in multiple pathways (Zhuang 
et al. 2009, Barbieri et al. 2012). Like TMPRSS2–ERG fusion SPOP mutations seems to increase 
invasion while not affecting proliferation (Barbieri et al. 2012). Likewise, SPOP mutations are found 
in high-grade intraepithelial neoplasia (HGPIN) suggesting that the alteration is early event in PCa 
carcinogenesis (Barbieri et al. 2012). 
 
SPOP mutant PCas have been associated also to mutations of CHD1 encoding chromodomain 
helicase DNA binding protein 1 (Barbieri et al. 2012, Blattner et al. 2014, TCGA 2015). These 
cancers have increased levels of DNA methylation as well as homogenous gene expression profiles 
(TCGA 2015). Also mRNA of serine peptidase inhibitor, Kazal type 1, SPINK1 has been found 
overexpressed in SPOP/CHD1 mutation carrying tumors (TCGA 2015). However, no clinically 
significant features or distinctive tumor morphology have been identified with this tumor type so far 
(Blattner et al. 2014). 
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Other frequent alterations in PCa include deletion of chromosome 8p21 (Bova et al. 1993, Taylor et 
al. 2010, TCGA 2015). This region contains tumor suppressor gene NK3-homeobox 1, NKX3-1 (He 
et al. 1997). Homeobox protein Nkx-3.1 is an androgen receptor responsive transcription factor that 
regulates prostate epithelial differentiation and proliferation (Bhatia-Gaur et al. 1999). Loss of NKX3-
1 expression has been correlated to PCa progression with most metastases completely lacking its 
expression (Bowen et al. 2000). In addition, even heterozygous deletion of the gene has been shown 
to cause hyperplasia and dysplasia of prostate epithelium in mouse studies (Bhatia-Gaur et al. 1999). 
More recently it has been shown to regulate response to DNA damage by guiding repair machinery 
to sites of DSBs in vitro (Bowen & Gelmann 2010). Thus the gene has dualistic role in PCa, favoring 
slight decrease, allowing proliferation and less confined differentiation state, and at the same time 
slight increase in the mutational rate due to less effective damage repair (Shen & Abate-Shen 2010). 
 
In contrast, q arm of the chromosome 8 is among the most frequently amplified in PCa (Taylor et al. 
2010, TCGA 2015, Robinson et al. 2015). The region contains the aforementioned AR coactivator 
gene NCOA2 as well as v-myc avian myelocytomatosis viral oncogene homolog, MYC, encoding c-
MYC, a master regulator of transcription (Taylor et al. 2010).  
 
C-MYC is frequently overexpressed in various hematological malignancies and colorectal cancer 
(Dang 2012). Its various functional roles are related to proliferation and growth, for instance by 
promotion of cell cycle progression and replication as well as stimulation of cap dependent translation 
(Dang 2012). In mouse prostate, c-MYC drives carcinogenesis together with lesions such as loss of 
Nkx3.1, which is also a potential target gene of c-MYC (Ellwood-Yen et al. 2003). In PCa c-MYC 
overexpression has also been associated with development of treatment resistance toward ADT as 
one alternative to AR alterations (Bernard et al. 2003, Gundem et al. 2015). Although not located in 
the same chromosome, amplification of another MYC gene family member, MYCL, has also been 
linked to primary PCa in one report (Boutros et al. 2015). Despite this wealth of knowledge, MYCs 
role in PCa remains incompletely defined as it is altered only in only under 10 % of primary PCas 
and has not been associated with alterations of any other driver gene or disease subtype in specific 
(TCGA 2015). 
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2.3.2.3 MicroRNAs in PCa carcinogenesis 
Like protein coding genes miRNAs can act as oncogenes (oncomiRs) or tumor suppressors depending 
on their target genes. It is not therefore surprising that expression of some miRNAs is similarly 
dysregulated as that of some protein coding genes in the setting of cancer.  For example, miR-21 is 
an oncomiR overexpressed in variety of human solid tumors including PCa (Volinia et al. 2006, Ambs 
et al. 2008) and targets PTEN in hepatocellular carcinoma (Meng et al. 2007). In PCa miR-21 has 
been shown to be androgen inducible in AR positive cell lines and to increase cell proliferation in 
vitro, increase tumor xenograft growth in mice and even to drive androgen independent progression 
(Ribas et al. 2009). 
 
Both global upregulation (Volinia et al. 2006, Ambs et al. 2008, Song et al. 2015) and downregulation 
(Porkka et al. 2007, Ozen et al. 2008, Martens-Uzunova et al. 2012) of miRNA expression have been 
reported in prostate cancer. It is tempting to think that the changes are related to changes in the 
miRNA biogenesis pathway. Few studies (Chiosea et al. 2006, Ambs et al. 2008, Martens-Uzunova 
et al. 2012) have studied expression of miRNA biogenesis pathway components in prostate cancer. 
Ambs et al. found moderate overexpression of microprocessor complex subunit DGCR8 and DICER1 
(Ambs et al. 2008). Chiosea et al. also found Dicer components to be overexpressed, whereas 
Martens-Uzunova et al. did not find the connection (Chiosea et al. 2006, Martens-Uzunova et al. 
2012). It is thus unlikely that there are major changes in miRNA biogenesis. 
 
The miRNA expression profiling studies so far have mostly used quite small cohorts, have variability 
in miRNA preparation and detection platforms and use different control samples, for instance normal 
adjacent tissue, BPH samples or tissue from healthy individuals, which makes comparison less 
reliable (Fabris et al. 2016, Ozen et al. 2008, Song et al. 2015). Nevertheless, there are some miRNAs 
whose expression patterns in PCa remain consistent between multiple studies (listed by Fabris et al. 
2016). For example, miR-145 has been found to be downregulated in total of five studies (Ambs et 
al. 2008, Porkka et al. 2008, Ozen et al. 2008, Martens-Uzunova et al. 2012, Larne et al. 2013) and 
to target oncogene MYC in molecular level (Sachdeva et al. 2009).  
 
The field of miRNA profiling now most urgently needs revision of the current findings with larger 
cohorts. The completion of this task has been made greatly more accurate and comprehensive by the 
advances in the sequencing technology (Song et al. 2015). It is now possible to sequence the whole 
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small RNA transcriptome without any presumptions about the tissue miRNA content, which makes 
it possible to detect novel miRNAs and variation in the lengths of the mature miRNA (Song et al. 
2015). In addition, high-throughput methods could be used to give directional evidence of miRNA–
target interactions by identifying inverse correlations in expression levels in the multi-omics data. 
 
2.3.3 Screening and diagnosis  
Men with prostate cancer have typically presented to the clinic with difficulties in urination (Virtanen, 
Hervonen 1995). The clinical investigations that follow are serum PSA test, digital rectal examination 
or rectal ultrasonography and if anything suspicious is found, taking of multiple needle biopsies from 
the gland (Attard et al. 2016, Shen & Abate-Shen 2010). 
 
PSA screening revolutionized prostate cancer diagnosis when it was introduced as a primary prostate 
cancer biomarker in the early 1990s (Prensner et al. 2012). As the serum PSA levels are very low in 
a healthy individual, the test is very sensitive in detecting such architectural changes in the prostate 
epithelium and vascularization that allow PSA leakage to the circulation (Lilja et al. 2008). However, 
such changes do not always occur during carcinogenesis. The prevalence of prostate cancer in biopsy 
among men with serum PSA levels under 4 ng/ml, a commonly used serum PSA threshold, was ~15 
% in one study (Thompson et al. 2004). On the other hand the prostate architecture may change as a 
consequence of other pathological states including inflammation and BPH (Nadler et al. 1995). 
 
BPH is a common disease in older men. Depending on definition and geographical location, as much 
as almost 3 % of men 40 – 49 years old and 23 - 30 % of men aged 80 have been estimated to have 
BPH (Verhamme et al. 2002, Speakman et al. 2015), which decreases the credibility of PSA as a 
reliable marker for early detection of prostate cancer. 
 
Despite these problems in specificity and sensitivity, higher serum PSA levels have been significantly 
correlated with PCa with more advanced cancers having even more elevated levels (Stamey et al. 
1987, Pinsky et al. 2007). Moreover serum PSA levels have been found to be useful predictor of 
prostate cancer death even ten years before when measured first under age 50 (Vickers et al. 2013). 
Nonetheless, only fraction of the patients can benefit from the screening, because many of the prostate 
cancers detected with serum PSA measurements are indolent and treatment can potentially lead 
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reduction of the patients’ quality of life because of adverse events such as pain, anxiety and sexual 
dysfunction (Prensner et al. 2012).  
 
For these reasons population based screening with PSA is not currently recommended neither in 
Europe or the USA. This conclusion has been reached in two ongoing longitudinal studies 
investigating efficacy of PSA screening (ERSPC in Europe and PLCO in USA) in preventing prostate 
cancer mortality even if a slight reduction in mortality in the screening group in comparison to the 
control group was observed in the ERSPC study (Andriole et al. 2012, Schröder et al. 2014). However 
screening of men who want early diagnosis should not be denied (Schröder et al. 2014). 
 
The various imperfections associated with PSA as a prostate cancer biomarker emphasize the need 
of new biomarkers that would ideally be non-invasive and have better prognostic value than PSA 
(Prensner et al. 2012). Together with this kind of new biomarker, screening with PSA could prove to 
be both sensitive and selective (Lilja et al. 2008).  
 
MiRNAs have been discussed as such new biomarkers: they are readily detectable in blood plasma, 
resist degradation (Michell et al. 2008) and their expression patterns change during the course of PCa 
(Mahn et al. 2011). The problem with miRNAs is that no single miRNA is specific enough to 
distinguish PCa from healthy tissue. On the other hand, it takes time and effort to validate a miRNA 
signature that is reproducible (Fabris et al. 2016) and if a blood based test is in question, present in 
blood in sufficient amounts (Mahn et al. 2011). This is also further complicated by the notions that 
miRNA profile of an individual changes during the course of aging (Liang et al. 2009) and the release 
of miRNAs is a selective process at least in some contexts (Pigati et al. 2010). Currently no such large 
scale studies have been conducted that the validation of this kind of panel would need, although 
several candidates of miRNAs for detection of the disease, distinguishing aggressive forms or 
biochemical recurrence after androgen deprivation therapy have been presented (Fabris et al. 2016). 
 
Other possibilities for new prostate cancer biomarkers are also emerging including PCA3, a long 
noncoding RNA that is only detected in PCa and not in BPH (Prensner et al. 2012). In addition, 
TMPRSS2-ERG fusion gene mRNA detection could prove to have prognostic power (Prensner et al. 
2012, Rubin et al. 2011). Despite being present only in just under half of the PCas, it is cancer specific 
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and the fusion is an early event in cancer progression providing enhanced ability to identify 
potentially more aggressive cancer cases at an early state (Rubin et al. 2011, Perner et al. 2007). 
 
In the absence of decisive noninvasive biomarkers, prostate biopsy remains golden standard of 
diagnosis. There are three types of prostate biopsies: needle biopsies that are maybe the most common 
procedure for suspected prostate cancer cases, transurethal resections of the prostate (TURPs) that 
have been used to treat lower urinary track symptoms (Epstein 2010) and the prostatectomies which 
are not done to make a diagnosis but rather as a surgical treatment for localized prostate cancer 
(Heidenreich et al. 2014a). It has to be said that even needle biopsy or TURP may not be decisive 
because of possible sampling errors and in the prognostic point of view a higher grade cancer could 
be missed because of the multifocality of prostate cancer (Epstein 2010, Fabris et al. 2016). 
 
Prostate intraepithelial neoplasia (PIN) and especially high-grade PIN (HGPIN) has been considered 
as the main precursor lesion of prostate carcinoma (Bostwick & Qian 2004). PIN is characterized by 
overgrowth of acinar or ductal luminal cells into the gland lumen as opposite to BPH where the 
proliferation occurs in the underlying basal cells (Bostwick & Qian 2004, Berman & Epstein 2014). 
In HGPIN the gland’s basal cell layer can also be discontinuous, indicating change towards more 
invasive phenotype. The carcinoma is indeed only distinguished from HGPIN by invasion to prostate 
stroma (Bostwick & Qian 2004). Invasive carcinoma is also often found together with HGPIN or in 
subsequent biopsies of the same patient (Netto & Epstein 2006). This is especially true if the HGPIN 
found is TMPRSS2-ERG fusion positive (Park et al. 2014). 
 
Recently Haffner et al. published evidence that at some occasions TMPRSS2-ERG gene fusion 
positive and PTEN negative carcinoma could form HGPIN mimicking structures in a retrograde 
manner (Haffner et al. 2016). This does not necessarily challenge the station of the HGPIN as a 
precursor of prostate cancer, but rather describes an important subset of cases misinterpreted as 
HGPIN. From the clinical point of view, the finding is relevant because a structure resembling a 
precursor lesion could actually prove to be aggressive cancer (Haffner et al. 2016). 
 
The fundamental property of cancer and the ultimate criterion for cancer diagnosis is the ability of 
cancer cells to invade into surrounding tissue (Berman & Epstein 2014). This criterion is met by all 
malignant neoplasia, although it has to be acknowledged that not all cancers are life threatening 
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(Berman & Epstein 2014). As discussed previously, many prostate cancers are indolent by nature and 
distinguishing the aggressive cancers still remains a major clinical obstacle today (Attard et al. 2016). 
 
2.3.4 Prognosis and treatment 
One of the most widely used mean to categorize prostate tumors to make prognosis is the Gleason 
scoring system. It is based on pathologist’s evaluation of architectural patterns of the tumor 
(Mellinger et al. 1967). This means the gland appearance from well differentiated separate glands to 
poorly differentiated glands showing spread of epithelial cells into the healthy prostate tissue (Epstein 
2010). The Gleason score is obtained by adding up two of the most prominent or in the case of needle 
biopsy the highest and the most prominent tumor patterns (Epstein 2010). Low score cancers include 
all scores from two to six and generally under Gleason score six cancers are not diagnosed anymore  
(Epstein 2010). Low score cancers generally do not metastasize and are curable (Ross et al. 2012, 
Epstein 2010). On the other hand, high scoring cancers Gleason 8-10 are more aggressive and should 
be treated as high risk cases (Heidenreich et al. 2014a).  
 
In addition to Gleason score, tumor stage is assessed by investigating tumor status: TNM staging 
reviews the size or invasiveness of the primary tumor T, status of tumor spread in the regional lymph 
nodes N and possible metastases M, which are detected by CT or MRI bone scans (Shen & Abate-
Shen 2010, Damber & Aus 2008).  
 
The poorly differentiated and well progressed tumors especially with distant metastases have the 
worst prognoses (Damber & Aus 2008). Luckily, most prostate cancers diagnosed are in the organ 
confined stage (Damber & Aus 2008). Treatment of these cancers varies from active surveillance 
without curative treatment to prostatectomy or external-beam radiotherapy or brachytherapy (internal 
radiotherapy) depending on patient age and the diagnostic factors such as serum PSA levels and the 
tumor Gleason score and TNM stage and number of positive needle biopsies (Damber & Aus 2008, 
Heidenreich et al. 2014a, Attard et al. 2016). In addition, newer and less frequently used treatments 
include high-intensity focused ultrasound and cryotherapy (Heidenreich et al. 2014a, Attard et al. 
2016).  
 
The life expectancy for patients with clinically localized prostate cancer is generally good as most 
prostate cancer deaths result from metastatic disease. However, locally advanced disease might be 
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life threatening too as it is associated with the risk of occult metastasis (Damber & Aus 2008). For 
these patients, adjuvant androgen deprivation therapy (ADT) is the best choice together with radical 
prostatectomy or radiation therapy as a primary treatment (Heidenreich et al. 2014a, Attard et al. 
2016). 
 
ADT has been the most effective available treatment for locally advanced or metastatic prostate 
cancer ever since it was established in the 1940s (Huggins & Hodges 1941, Damber & Aus 2008). 
The castration is done most often chemically nowadays, allowing reversibility and intermittency of 
the therapy, which reduces adverse effects (Heidenreich et al. 2014b). These drugs affect systemically 
by blocking the release of luteinizing hormone from the pituitary gland, which in turn prevents 
synthesis of androgens in the testicles (Heidenreich et al. 2014b). However, with this approach it is 
not possible to reach full androgen ablation as adrenal gland as well as some prostate cancer cells 
themselves can synthesize androgens de novo, independent of luteinizing hormone release 
(Stanbrough et al. 2006, Locke et al. 2008). Nevertheless, this does not mean that chemical castration 
would be inferior to other means of preventing PCa cells from using androgens, as these mechanisms 
of resistance probably represent only small subset of routes to castration resistance. 
 
Antiandrogens are steroidal or nonsteroidal molecules that bind to androgen receptor without 
activating it. These AR-antagonists can be used in combination with or optionally to castration 
(Heidenreich et al. 2014b, Attard et al. 2016). However, chemical castration or combination therapy 
remains the preferable option as the traditional antiandrogens such as bicalutamide are not as effective 
as castration and there is no evidence from larger trials comparing the benefits of castration and newer 
antiandrogens, such as enzalutamide, as a monotherapy for hormone naïve cancer (Attard et al. 2016, 
Pchejetski et al. 2014). Moreover, at least AR-antagonists such as bicalutamide, cyproterone acetate 
and flutamide have been found to act as agonists of AR in the setting that AR is overexpressed and 
the balance of coactivators and corepressors has been upset (Chen et al. 2004). 
 
In addition, there is newer drug, abiraterone acetate, that targets the synthesis of testosterone by 
inhibiting CYP17A1 enzyme irreversibly (Pchejetski et al. 2014, Attard et al. 2008). The greatest 
advantage of this drug is that it works systemically inhibiting enzymes in the testicles, adrenal cortex 
and the PCa cells. However, at the same time it leads to the need of steroid supplementation often in 
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the form of prednisone to overcome side effects of excess mineralocorticoids that are synthesized in 
the metabolic pathway upstream of CYP17A1 (Attard et al. 2008). 
 
Although ADT initially leads to sound response with decreased tumor burden and relief of symptoms, 
the disease inevitably gains resistance to the treatment (Damber & Aus 2008). The most effective 
drugs in the treatment of CRPC are the previously mentioned enzalutamide and abiraterone acetate 
as well as cytotoxic agents such as docetaxel and cabazitaxel (Attard et al. 2016). Nevertheless, these 
drugs can only provide prolonged survival and temporal relieving of symptoms instead of cure for 
the patients, as the cancer eventually gains resistance. 
 
The use of these most promising drugs, enzalutamide and abiraterone acetate, in the setting of 
hormone naïve patients would be the next rational approach to improve treatment of prostate cancer 
despite their expenses (Pchejetski et al. 2014, Attard et al 2016). In addition, docetaxel may benefit 
these patients (Vosboynik et al. 2014). 
 
The fact that the advanced disease previously perceived as “androgen independent” commonly 
remains androgen dependent has given hope of finding new androgen signaling targeting drugs that 
would not allow development of resistance to the treatment. Nonetheless, it seems that these bulk 
treatments may not be viable options for all the patients, for example those possessing AR gene 
mutations (Robinson et al. 2015) and for this reason further research focusing into the molecular 
mechanisms of prostate cancer has to be continued.  
 
However, there probably is not another “one drug for all prostate cancers” type of solution as it is the 
case with androgen signaling pathway targeting drugs. The heterogeneity of PCa forces to find targets 
that not necessarily all cases share, which raises the cost and effort of tackling the disease. While on 
the other hand this may be compensated by the possibility of finding drugs that are effective in limited 
subtypes of cancer of multiple different organs (Courtney et al. 2010). Nevertheless, with the ever 
improving knowledge of the biology of prostate cancer it is possible to take more effective and 
personalized approach into PCa management. And there certainly is not lack of alternative targets. 
For example, alterations in PI3K and Wnt signaling could be targeted with existing drugs as well 
(Courtney et al. 2010, TCGA 2015, Robinson et al. 2015). The unquestionable benefits of this 
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approach have already been proven in a trial in which patients with mutations in DNA damage repair 
genes were treated with DNA damage repair impairing drug olaparib (Mateo et al. 2015).  
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3. OBJECTIVES 
The purposes of this study were to assess whether miR-32 regulates expression of PI15 and how PI15 
overexpression affects to the growth and viability of PCa cells. Exogenous source of both PI15 (in  
the form of plasmid vector) and miR-32 (in the form of pre-miR) were used to have higher levels of  
expression and thus bigger changes that would be easier to monitor both in the RNA and protein level.  
  
In addition, two new vectors were needed for the generation of stable PI15 overexpressing cell lines 
and for luciferase reporter assay. The first would need to have marker for antibiotic selection in 
mammalian cells and the second the coding region of luciferase marker gene with the 3’UTR of PI15 
to allow possible binding of miR-32. 
 
Thus, the objectives were: 
1. To assess whether PI15 is miR-32 target gene 
2. To construct suitable vectors for generating PCa cell lines stably expressing PI15 and for the 
luciferase assay 
3. To observe effects of PI15 overexpression on PCa cell lines’ growth and cell viability 
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4. MATERIALS AND METHODS 
4.1 Sanger sequencing 
Sequencing was used to confirm that the commercial pCMV6-XL4 PI15 plasmid (Origene 
technologies, Rockville, MD USA) was correct and contained the whole gene with the long 3’ UTR 
region (full length 6732 bp, refseq id: NM_015886.3). Sequencing primers were generated using the 
Primer BLAST tool by NCBI (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and the best 
primers were selected on the preference that they did not have excessive secondary structures within 
the primer sequence as predicted by mFold web tool (Zuker et al. 2003). In addition, both PI15 ORF 
and luc2P cloning was validated by sequencing. 
 
Samples were prepared for the sequencing by amplification with master mix containing fluorescent 
terminator nucleotides. Simple master mix was prepared as follows: 1 µl BigDye terminator mix 
(Thermo Fisher Scientific, Waltham, MA USA); 1,5 µl of 5x BigDye buffer and 5,5 µl of nuclease 
free water. Each reaction was supplied with 300 ng of sample DNA in the volume of 1 µl and 1 µl of 
5 µM sequencing primers. The PCR reactions were thermally cycled according to reagent 
manufacturer’s instructions. Sequencing primers are denoted with “seq” in the primer name in table 
1. List of primers. In addition, primers VP1.5 and XL39 provided by Origene Technologies were used 
for sequencing. 
 
Table 1. List of primers 
# Primer name Primer sequence 
1. VP1.5 GGACTTTCCAAAATGTCG 
2. PI15_Seq_for2 GGCCAAAATCTATCTGTACG 
3. PI15_Seq_for3 TGTGCTAATCTTGTTTTCCTC 
4. PI15_Seq_for4 CTTATTTGAGTCCACCAAAGG 
5. PI15_Seq_for5 GATGGAGAGCTTCAGAATGG 
6. PI15_Seq_for6 TCAGGTTGTGTAATGCTCCCG 
7. PI15_Seq_for7 AGATGGCTACACTAAGTTCC 
8. PI15_Seq_for8 ACACACTTAGGCAATAGTCC 
9. PI15_Seq_for9 GACACAGTCTTAATGTTTCTGG 
10. PI15_Seq_for10 ACTTTGGTGTAGGTTCTTCC 
11. PI15_Seq_for11 TGTTGATGGCTTTAGTAATGCTCC 
12. PI15_Seq_for12 CCATGATTTTCCAGTTCTGAGGC 
13. PI15_Seq_for13 CACATGCAAAACTCCAACCTGT 
14. PI15_Seq_for14 GTTAGCAGTCTTTCAGTTTGG 
15. PI15_Seq_rev1 ATGAACATGGTACCCCTACT 
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16. PI15_Seq_rev2 AATGTGTGTTAAGAAGTCCCA 
17. PI15_Seq_rev3 TGGCTTATTACTTGCTCCAC 
18. PI15_Seq_rev4 GGAGCATTACACAACCTGAA 
19. PI15_Seq_rev5 ATTCCATGAATAAGCTTCCCT 
20. PI15_Seq_rev6 ACATTTTAGGTGCTGTCAGA 
21. PI15_Seq_rev7 ACAAAAGAGATTACACCCAGT 
22. PI15_Seq_rev8 ATATGTATCCAAGCACCAGC 
23. XL39 ATTAGGACAAGGCTGGTGGG 
24. PI15_NheI AATTATGCTAGCCCACCCCTCAAAATGATAGC 
25. PI15_BamHI ATAAATGGATCCGTAAACTTATTTAAACCAGTACAGG 
26. Luc2P_EcoRI_for2 AACTATGAATTCTGATAATATGGCCACATGGAAG 
27. Luc2P_HpaI_rev ATATGAGTTAACAATTATTACACGGCGATCTTGC 
28. Luc2P_PstI_rev ATATGACTGCAGAATTATTACACGGCGATCTTGC 
29. T7 promoter TAATACGACTCACTATAGGG 
30. BGH_rev TAGAAGGCACAGTCGAGG 
31. Luc_for CGCACATATCGAGGTGGACA 
32. Luc_rev AACTTGCCGGTCAGTCCTTT 
33. PI15_F GGAAGCGCTACATTTCGCAG 
34. PI15_R CCAAGCCTCTGCCGATTTTG 
35. TBP3 rev GAGCCATTACGTCGTCTTCC 
36. TBP3 for GGGGAGCTGTGATGTGAAGT 
 
After the PCR the samples were precipitated by centrifugation with absolute ethanol supplied with 
sodium acetate. The precipitated samples were washed with 70 % ethanol and dissolved into Hi-Di 
formamide (Thermo Fisher Scientific). The sequencing was done by the University of Tampere core 
facility in ABI3130xl Genetic Analyzer (Applied Biosystems/ Thermo Fisher Scientific). 
 
4.2 Subcloning of PI15 and luc2P 
To observe the effects of overexpression of PI15 gene, the genes’ open reading frame (ORF) from 
the pCMV6-XL4 PI15 plasmid was subcloned into pcDNA3.1 (+) plasmid that contains neo antibiotic 
resistance gene against Geneticin. In addition, another plasmid was constructed for luciferase reporter 
assay. The pCMV6-XL4 plasmid was used as the backbone of this reporter plasmid in which the PI15 
coding region was replaced by luc2P gene from pHIV luciferase plasmid 
(https://www.addgene.org/21375/; 11.4.2016) kindly provided by prof. Anne Kalllioniemi’s group 
(BioMediTech, University of Tampere, Tampere, Finland). The subcloning of the luciferase gene 
was designed by analyzing the PI15 3’ UTR with the University of Waterloo web tool WatCut 
(http://watcut.uwaterloo.ca/template.php?act=restriction_new; 11.4.2016) for suitable cut sites. Two 
different versions of the plasmid were designed to preserve different lengths of the UTR. This was 
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done by using two different luc2P reverse primers with different cut sites for the 3’ end of the PI15 
3’ UTR region where the miR-32’s supposed binding site (Figure 2) is located. 
 
     3' acgUUGAAUCAUUACACGUUAu 5' hsa-miR-32 
           || || ||  ||||||||  
4407:5' uaaAAAUUUGU--UGUGCAAUa 3' PI15 
 
Figure 2. Hsa-miR-32/PI15 Alignment. Alignment from microrna.org (Betel et al. 2008 and 2010). 
 
Mutation primers were designed for both cloning works manually by searching for sufficiently long 
stretches of DNA with preferentially 2 or 3 purines at the end of the 3’ end. In addition to the sequence 
complementary with PI15, cut sites were added for restriction enzymes NheI and BamHI for the 5’ 
end and 3’ end primer respectively. For luc2P primers, cut sites for EcoRI and PstI or HpaI were 
added to the 5’ end and 3’ end primers respectively. In addition, 6 random nucleotides were added to 
the primers before cut site to ensure proper function of the restriction endonucleases. 
 
To ensure that the PCR is as specific as possible the primers were assessed with sequence based 
bioinformatics tools for approximately equal melting temperature: Oligo calc (Kibbe et al. 2007), 
melting temperatures of possible secondary structures within primer sequence: mFold (Zuker et al. 
2003) and formation of primer dimers: Multiple Primer Analyser by Thermo Fisher Scientific 
(https://www.thermofisher.com/fi/en/home/brands/thermo-scientific/molecular-biology/molecular-
biology-learning-center/molecular-biology-resource-library/thermo-scientific-web-tools/multiple-
primer-analyzer.html#; 11.4.2016, Breslauer et al. 1986). Primer sequences are listed in table 1 with 
order numbers 24 and 25 for PI15 ORF cloning primers and 26, 27 and 28 for luc2P cloning primers. 
 
The PI15 ORF was subloned by traditional restriction–ligation method. PCR conditions were 
optimized for Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific) to minimize errors 
during amplification of the inserts. The PCR products and the empty pcDNA3.1 (+) plasmids where 
double digested with the BamHI and NheI restriction enzymes according to enzyme supplier protocol 
(New England Biolabs, Ipswich, MA USA) and extracted from 1 % agarose gel after electrophoresis 
with QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) to check right size of the amplicons 
and to get rid of any unspecific product. 
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PI15 ORF was ligated to the pcDNA3-1(+) vector with T4 DNA ligase (Thermo Fisher Scientific) 
according to manufacturer’s protocol. Next 4 µl of the ligation mix was applied on One Shot® TOP10 
Chemically Competent E. coli cells (Thermo Fisher Scientific) and after 15 min incubation the cells 
were transformed by 45 s heat shock in 42 °C water bath. The transformed bacteria were incubated 2 
min on ice and supplied with 150 µl of SOC medium (Thermo Fisher Scientific) and streaked on LB-
agar plates with 50 µg/ml ampicillin and cultured overnight in 37 °C. 
 
On the next day, four colonies were picked and grown in LB-broth with 100 µg/ml ampicillin. 
Plasmids were extracted from the bacteria with GenElute™ Plasmid Miniprep Kit (Sigma-Aldrich, 
St. Louis, MO, USA) and the plasmids were checked for the insert by PCR with primer pair 29 and 
15 (Table 1.), 2 and 30 and 29 and 30, the amplified regions spanning the 5’ cloning site, 3’ cloning 
site and the whole inserted region respectively. The presence of right sized products was checked first 
by agarose gel electrophoresis and the insert region was then sequenced, as previously described, 
with primers 2, 16, 29 and 30 to confirm that the gene had been successfully subcloned. 
 
TOPO-TA cloning was used for the luc2P subcloning. The insert was first amplified with the primers 
26 and 27 or 28 as described previously for PI15 ORF. However, for TOPO-TA cloning another 
amplification was done for these products with Maxima HS Taq polymerase (Thermo Fisher 
Scientific) both to increase yield and to generate the TA overhangs required for the cloning technique. 
Subcloning to the pCR-XL-TOPO vector was carried out by TOPO-TA Cloning Kit (Invitrogen / 
Thermo Fisher Scientific) after manufacturer’s instructions and TOP 10 chemically competent cells 
were transformed as described previously with the following exception: As the selection marker of 
pCR-XL-TOPO plasmid is bactericidal antibiotic kanamycin, the bacteria were incubated 1 h in 37 
°C in the SOC medium before streaking onto the LB-agar kanamycin plates to allow expression of 
the resistance gene before introducing them to the antibiotic. 
 
Subcloning was confirmed with colony PCR and restriction analysis. The primer pair 31 and 32 was 
designed to amplify 1458 bp region within the luc2P gene and the restriction enzymes EcoRI, PstI 
and HpaI (Thermo Fisher Scientific) were used both alone for linearization and in pairs (EcoRI and 
PstI, EcoRI and HpaI) to separate the inserts. After the digestion, the inserts and similarly digested 
pCMV6-XL4 vectors containing the PI15 3’ UTR were extracted from gel and ligated with T4 DNA 
ligase with an elongated ligation time of 4 h. After transformation and liquid culturing of the positive 
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clones, the new plasmids were again tested with colony PCR with primer pair 31 and 32 ( luc2P) and 
29 and 20 (region spanning the whole insert region including cloning sites). The plasmid was also 
sequenced with the primers 20, 21, 29, 31 and 32. 
 
4.3 Cell lines 
PC-3 and LNCaP from American Type Cell Collection (Manassas, VA USA), were the cell lines used 
in the experiments of this work. PC-3 cells were cultured in Ham’s F-12 (Lonza, Basel, Switzerland) 
and LNCaPs in RPMI-1640 (Lonza) medium supplemented with 10 % fetal bovine serum and 1 % 
of L-glutamine in 37 ᵒC and presence of 5 % CO2.  The cells were passaged twice a week and were 
not allowed to reach full confluency. 
 
4.4 Transfections and generation of stable cell lines 
The expression vectors were checked by transfecting PC-3 and LNCaP cell lines with either pCMV6-
XL4 PI15 or pcDNA3.1(+) PI15 ORF and by comparing PI15 expression of these cells into empty 
vector transfected controls. The effects of miR-32 on PI15 expression was studied in co-transfection 
experiments, where the commercial pCMV6-XL4 PI15 vector or empty control vector and pre-miR-
32 or pre-miR control (Ambion / Thermo Fisher Scientific) were used. Transfections were also made 
to generate cell lines with PI15 gene stably integrated into their genomes.  
 
Mono-transfections were done with the following protocol. 400 000 cells in 2 mls of medium were 
first seeded into six well plates. The cells were then transfected with mix containing 2 µgs of plasmid 
vectors and 4 µls of jetPEI DNA transfection reagent (Polyplus-transfection, Illkirch, France) in 200 
µl of 150 mM NaCl.  
 
In the case of stable transfection, the plasmid vectors (pcDNA3.1 (+) PI15) were linearized with BglII 
restriction enzyme (Thermo Fisher Scientific) before transfection to improve efficiency of genome 
integration. Also the transfection was scaled up by using two million cells, 10 µgs of the plasmid and 
20 µls of jetPEI to overcome the antibiotic selection burden. 
 
The antibiotic selection was started on day three after the transfection with 500 µM Geneticin (Gibco 
/ Thermo Fisher Scientific) for PC-3 and 300 µM Geneticin for LNCaP cells. The selection medium 
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was carefully replaced at least every third day until visible colonies were detected. The colonies were 
ring cloned and passaged onto bigger culture formats until sufficient amount for growth curve and 
metabolic rate analysis was reached. 
 
For co-transfections 250 000 cell were first seeded into six well plates in three replicates. In the next 
day the cells were transfected with mix containing 0,5 µgs of plasmid vector; 1,0 µls of 20 µM pre-
miR (for final concentration of 10 nM in 2 mls of medium) and 4 µls of jetPRIME (Polyplus-
transfection) in 200 µls of jetPRIME buffer (Polyplus-transfection). The co-transfections where 
repeated twice for RNA extraction. 
 
4.5 Growth curves and cell viability assays 
For the growth rate analysis 10 000 cells of each stable PI15 clone and control clone were seeded into 
24 well plates in six replicates. The cells were imaged on days 1, 3 and 4 after seeding with 10 x 
magnification with Olympus IX71 microscope with integrated OASIS automation control system and 
Surveyor imaging software version 5.5.5.26 (Objective Imaging Ltd., Cambridge, UK). The area of 
the cells in each well was then analyzed with ImageJ software (NIH, Bethesda, MD USA). The 
experiment was repeated three times for the PI15 overexpressing clones, however the two initial 
experiments did not contain proper empty vector transfected controls. 
 
AlamarBlue® Cell Viability Reagent (Thermo Fisher Scientific) was used as another measure to 
monitor growth and viability of the clones. The cells were seeded as with the imaging experiment, 
but there were two plates with six replicates for each clone because of the setup of the experiment. 
On day one after seeding the first six replicates were supplied with 50 µl AlamarBlue to the 500 µl 
of growth medium, put into the incubator and 100 µl samples were collected after one and two hours 
after the addition of the reagent. Same was repeated for the remaining six replicates on day four after 
seeding. The samples were stored in -20 °C, protected from light until fluorescence emission at 590 
nm following excitation at 560 nm was measured with Envision multilabel plate reader 
spectrophotometer (PerkinElmer, Waltham, MA USA). The fluorescence values of the day one 
samples were used to normalize the values acquired for the day four samples. 
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4.6 RNA extractions and reverse transcription 
Cells were collected approximately 48 hours after transfections by applying appropriate amount (8 
ml for T75 flask, 1 ml for well of a six well plate) of TRI Reagent (Thermo Fisher Scientific) onto 
them while keeping them on ice. All RNA extractions were carried out with TRI Reagent according 
to manufacturer’s instructions. Glycogen (RNA grade) (Thermo Fisher Scientific) was added to the 
sample with isopropanol when extracting RNA from samples cultured in 6 well plate format for 
enhanced precipitation of the RNA. 
 
Reverse transcription was used to generate cDNA suitable for qRT-PCR. Random hexamer 
oligonucleotides were used as primers to reverse transcribe the whole pool of extracted RNAs. 1000 
ng of RNA, as measured with the NanoDrop 1000 (Thermo Fisher Scientific) instrument, was used 
as starting amount of total RNA. The reactions were done with Maxima Reverse Transcriptase 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. 
 
4.7 SYBR-green and TaqMan qRT-PCR assays 
SYBR-green qRT-PCR method was used to measure the amount of PI15 transcript in transfected PC-
3 and LNCaP cells (primer pair 33–34). Data was normalized against the house keeping gene TBP 
(primer pair 35–36). For the test run, a pool of PC-3, LNCaP and 22Rv1 total RNA in 1:5 dilution 
series was used as a standard, but as the samples transfected with the PI15 plasmid were consistently 
over the scale of these wild type samples’ signal, total RNA pool from these transfected cells were 
used as a standard for the subsequent qPCRs. 
 
 Single SYBR-green master mix was prepared by adding 10 µls of 2x Maxima SYBR Green (Thermo 
Fisher Scientific) and 0,1 µls of 10 µM forward and reverse primers into 7,8 µls of water. 2 µls of  
each sample, standard and water each in duplicates were added and the plate was cycled with program 
with a suitable annealing temperature for each primer pair and the fluorescent signal was read after 
each thermal cycle in CFX96 Real-Time PCR Detection System (Bio-Rad, Hercules, CA USA). 
 
In addition to SYBR-green qRT-PCRs, TaqMan microRNA assay for quantitation of the amount of 
miR-32 in each sample was performed. RNU6B was used to normalize the amount of miR-32. PCRs 
for TaqMan were done in two parts according to Applied Biosystems’ (Thermo Fisher Scientific) 
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TaqMan MicroRNA assays protocol. First, 25 ng/µl dilutions of the samples’ and 250 ng/µl dilutions 
of the standards’ total RNA were used for reverse transcription. Single reverse transcription master 
mix contains 9,15 µl of nuclease free water, 1,5 µl of 10 x Reverse transcription buffer 0,15 µl of 10 
mM dNTPs, 0,2 µls of RNase inhibitor, 1 µl of RT primer and 1 µl of Multiscribe Reverse 
Transcriptase. 2 µl of sample were added to the master mix and the following PCR program was used 
for reverse transcription: 30 min at 16 ᵒC (priming), 30 min at 42 ᵒC (transcription) and 5 min at 85 
ᵒC (denaturation of transcriptase).  
 
In the next step TaqMan qRT-PCR was performed to quantify miR-32 in the samples. Master mix for 
single sample contains 7 µls of nuclease free water, 10 µl of 2x universal PCR master mix and 1 µl 
of TaqMan MicroRNA Assay 20x. Reverse transcribed samples were diluted in 1:15 and 2 µls of the 
dilutions were used for each reaction. Following program was run with the CFX96 Real-Time PCR 
Detection System: initial denaturation 10 min at 95ᵒC, 40 cycles of 15 s at 95 ᵒC, 60 s at ᵒ60. No 
duplicates of the samples were run for the TaqMan assay because of the large amount of samples. 
 
4.8 Protein extraction and determination of protein concentration 
Cells for protein extraction and western blot were collected 72 to 96 h after transfections. Cells were 
first rinsed with fresh phosphate buffered saline (PBS). 500 µl of ice cold PBS with 2x concentration 
of cOmplete protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) were applied onto 
the cells and they were scraped off and collected. The cells were then centrifuged in 800g for 3 min 
and the supernatant discarded. 
 
The cells were lysed by resuspending them with 80 µl of Triton X-100 lysis buffer (0,5 % Triton-X 
100, 300 mM NaCl in 50 mM Tris-HCL pH 7,4) supplied with 40 µl/ml 25 x cOmplete protease 
inhibitor cocktail, 10 µl/ml of 100mM DTT (Sigma-Aldrich), 10 µl/ml of 100 mM PMSF (Sigma-
Aldrich), and incubating them 15–30 min on ice. Next the suspensions were further degraded by ultra-
sonication with Bioruptor Sonicator (Diagenode, Liège, Belgium) the instrument set on high 
frequency, four times 30 seconds on and off. The suspensions where then centrifuged (10 min, 16 000 
g) to remove cell debris and supernatant containing the proteins was passed to clean tube. 
 
Because PI15 is a secreted protein, the culture medium was also collected as a sample for sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) and western blot (WB). The first 
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attempt of WB with medium containing serum lead to big smears in the membrane with no apparent 
marks of proteins the size of PI15 (~25 kDa). For this reason, in the second experiment the growth 
medium was replaced with 800 µl of serumless growth medium 24 h before collection. Before 
experiment the medium samples were centrifuged (10 min, 16 000 g). Undiluted medium was then 
used as sample for SDS-PAGE. Protein concentration was not measured from these growth medium 
samples. 
 
The protein concentration was measured with DC™ Protein Assay (Bio-Rad), according to kit 
manufacturer’s instructions, although in some instances the BSA standard series was much more 
concentrated (0,5 mg/ml to 10 mg/ml) than instructed by Bio-Rad (0,2 mg/ml to 1,5 mg/ml). The 
absorbances of the samples were measured in 96 well plate in the Envision multilabel plate reader 
spectrophotometer at 750 nm. 
 
4.9 SDS-PAGE and western blot 
After measurement of the protein concentrations, the samples were diluted into the same 
concentration and prepared for PAGE with Red Loading Buffer Pack (New England Biolabs), (1/10 
volume of 1,25 M DTT as a reducing agent) according to the reagent supplier’s instructions. Details 
of the samples in each experiment are listed in Table 2. Western blot samples. 
 
Table 2. Western blot samples. Each column represents individual experiment. *Same samples as in the 
previous experiment. † The clone is stably transfected with PI15 plasmid but does not overexpress PI15 as 
assessed by qRT-PCR 
Cell lines LNCaP, PC-3 LNCaP, PC-3 LNCaP, PC-3 LNCaP*, PC-3* PC-3 PI15 
Medium 
sample 
- medium serumless 
medium 
serumless 
medium* 
- 
Controls empty vector empty vector empty vector + 
untransfected 
empty vector + 
untransfected* 
non 
overexpressing 
PC-3 PI15 clone† 
Trans-
fection 
pCMV6-XL4 
PI15 
pCMV6-XL4 
PI15 
pcDNA3.1 (+) 
PI15 
pcDNA3.1 (+) 
PI15 
Stable pcDNA3.1 
(+) PI15 
Amount 
of protein 
7,5 µg / well 21 µg / well 13 µg / well 13 µg / well 20 µg / well 
Antibody polyclonal 
rabbit-α-PI15 
polyclonal 
rabbit-α-PI15 
polyclonal rabbit-
α-PI15 
monoclonal 
mouse-α-PI15 
both 
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The samples were loaded into premade 12,5 % polyacrylamide gels (1 x running gel prepared by 
mixing 2,8 ml H2O; 2,25 ml of 1,5 M Tris buffer with pH 8,8; 180 µl 10 % W/V SDS solution; 3,75 
ml 30 % Acrylamide/Bis Solution (Bio-Rad), 10µl TEMED and 40 µl 10 % ammonium persulfate). 
In some instances, visible puffs of sample from well to another occurred, but their effect was 
minimized by leaving empty well between PI15 transfected and control (untransfected or empty 
plasmid) samples. The samples were run in Mini-PROTEAN® Tetra Cell Systems chamber (Bio-
Rad) ~30 min with 50 V to drive the samples into the border of stacking and running gels and then 
~1,5 h in 100 V until the edge of the sample buffer color marker emerged to the running buffer. 
 
The proteins were transferred into immobilon®-P (Merck & Co., Inc., Kenilworth, NJ USA) PVDF 
membrane for detection with PI15 antibodies. Membrane was activated with methanol, and semidry 
electro blotting was done by loading the Trans-Blot Semi-Dry System (Bio-Rad) apparatus with three 
whattmans that were dipped into semi dry transfer buffer, the membrane was then applied onto the 
whattmans, followed by the polyacrylamide gel and three more wet whattmans. Air bubbles where 
then removed by rolling with a measuring pipette gently over the top of the stack. At last the proteins 
were transferred by applying 80 mA current for 1 h. 
 
The membrane was rinsed with PBS and rocked for ~2 min in Ponceau S stain to check transfer of 
proteins and the stain was rinsed off with ddH2O. Next the membrane was blocked with 3 % bovine 
serum albumin (BSA) in PBS for 1h in room temperature or overnight in +4°C. Rabbit polyclonal  
(TA308594, Origene technologies) or mouse monoclonal (H00051050-M02, Abnova Corporation, 
Taipei city, Taiwan) antibody (0,5 µg/ml dilution with 1 % BSA; 0,1 % Tween-20 and 0,1 % NaN3 
in BPS)  against PI15 was then used to bind the protein by rolling in tube for 1h in RT. Membrane 
was washed by rinsing with PBS and rocking 3 x 5 min in PBS and 0,1 % Tween-20. The membrane 
was then rolled in secondary antibody, which was either swine-α-rabbit-HRP or rabbit-α-mouse-HRP, 
(both Dako / Agilent Tehcnologies, Santa Clara, CA USA) (1:5000 dilutions in BPS with 1 % BSA; 
0,1 % Tween-20) and washed similarly as before secondary antibody. 
 
Detection was done with Western Blotting Luminol Reagent (Santa Cruz Biotechnology inc., Dallas, 
TX USA) or SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and 
x-ray film. 
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4.10 Statistical testing 
All statistical testing was performed with IBM SPSS software version 20. Testing was applied to 
growth rate and cell viability assays to study statistical differences in these properties between PI15 
transfected clones and vector transfected controls. 
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5. RESULTS 
5.1 Subcloning of PI15 ORF 
To study the effects of stable PI15 overexpression to PCa cell lines, a plasmid containing the gene 
and a mammalian selection marker was needed. PI15 ORF from the commercial pCMV6-XL4 PI15 
vector was successfully subcloned to pcDNA3.1 (+) plasmid into NheI and BamHI restriction sites. 
The plasmid sequence spanning both restriction sites and the insert region were confirmed by Sanger 
sequencing. 
 
5.2 Subcloning of luciferase 
To investigate with the luciferase reporter assay whether the predicted interaction of miR-32 with the 
PI15 3’UTR has an effect on the protein expression, the luciferase gene luc2P was also cloned to the 
pCMV6-XL4 PI15 plasmid in the place of PI15 ORF. Two constructs with different lengths of PI15 
3’UTR region preserved (~1600 bps with HpaI restriction site and ~2150 bps with PstI restriction site 
in the 3’ end of the PI15 gene) were attempted. The cloning was successful with the 3’ primer 
containing PstI restriction site and this was confirmed by sequencing. Partial sequence (~81 %) of the 
coding region of luciferase gene was covered by the sequencing. In addition, the sequencing covered 
most of the 3’UTR of the PI15 gene from the luc2P gene towards the putative miR-32 binding site, 
but unfortunately not the putative binding site itself. 
 
The luc2P gene of the constructed vector was found to contain one non-synonymous mutation: 
424A<G or 142K>E. As to our knowledge this mutation is not present in any of the sequences 
deposited into the NCBI GenBank sequencing database. Because the sequence is critical for the 
protein structure, and in the case of luciferase reporter assay, a mutation may even compromise the 
usage of the plasmid, we next analyzed the sequence context of the mutated amino acid to assess its 
effects on the functionality of the mature protein. 
 
5.3 Effects of the luc2P mutation to the protein conformation 
The luc2P gene is a codon optimized luciferase developed by Promega corporation (Fitchburg, WI 
USA) based on the Photinus pyralis luciferase. Using the roentgen crystallography based structure of 
WT P. pyralis luciferase (PDB structure: 4g36, Sundlov et al. 2012) the mutated amino acid was loca- 
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Figure 3. Mutation site (WT) in the luciferase enzyme. The mutation site 142K is the blue (positive charge) 
bulge in the middle of the picture. The amino acid is fully exposed to the solution in this roentgen 
crystallographic model. Structure PDB coordinates 4g36 (Sundlov et al. 2012). Image from DeepView - Swiss-
PdbViewer v4.1 (Guex et al. 1997).  
 
Figure 4. Stick model of the mutation site in the luciferase enzyme. A The WT structure of the luciferase.  
B The same structure with the mutation 142K>E. In the mutant enzyme the Glu 142 might form ionic bond 
with Lys 141. Structure A PDB coordinates 4g36 (Sundlov et al. 2012), structure B modified from 4g36.  Image 
from DeepView - Swiss-PdbViewer v4.1 (Guex et al. 1997). 
A B 
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ted to the protein surface (Figure 3). It is not part of any secondary structure in this PDB structure 
and seems to interact only with the preceding amino acid Lys141, which is also positively charged 
(see Figure 4A). When the lysine 142 is replaced by glutamate (Figure 4B) the two amino acids could 
form an ion pair, potentially even stabilizing the unstructured region in some conditions. 
 
 
5.4 PI15 and miR-32 co-transfections 
The effect of miR-32 on PI15 expression was studied by transiently transfecting the original pCMV6-
XL4 PI15 plasmid and pre-miR-32 or negative control miR into LNCaP and PC-3 cells and observing 
the effects on PI15 mRNA expression. At first, we checked by mono-transfections and qRT-PCR that 
the plasmid worked (data not shown). The RNA level expression was analyzed with qRT-PCR and 
the data was analyzed by the comparative CT method (Livak & Schmittgen 2001, Schmittgen et al. 
2008). The co-transfection protocol was also working, as control samples (both WT and empty 
vector) present no to little PI15 expression, whereas the samples transfected with the gene containing 
plasmid have higher levels of expression (See figures 5 and 6A). Transfections were repeated, 
because some samples had low RNA concentrations after the extraction on the first attempt (see figure 
5). However, the SYBR-green qRT-PCR did not provide clear evidence of whether miR-32 controls 
the expression of PI15 or not.  
 
To check whether the transfection protocol was working also on behalf of miR-32, we conducted a 
TaqMan assay to determine miR-32 expression in each sample. Unfortunately, signal was detected 
only from the LNCaP cells of the second experiment (Figure 6B). However, the success of the 
transfection was again confirmed with the TaqMan data, as the samples transfected with pre-miR-32 
presented much higher expression of miR-32. Although the pattern of the last two samples in Figure 
6B looks promising, there is not enough samples to state whether miR-32 regulates the expression of 
PI15. 
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Figure 5. PI15 expression in the mRNA level in co-transfected LNCaP (A) and PC-3 (B) cells, first 
experiment. The first samples shown on the left side of the graphs are WT controls. Next are the cells 
transfected with control vector or PI15 and negative control miR or pre-miR-32. There were three replicates 
in each transfection (separate columns denoted with numbers) and each of these had two replicates in qRT-
PCR. Relative expressions were calculated with comparative CT method with TBP as an internal control gene. 
Error bars (± standard deviations, s.ds.) are calculated for qRT-PCR replicates. A The missing replicates from 
transfection (LNCaP ctrl 2 and 3) are due to low concentration of RNA from the extraction. The qRT-PCR 
replicate of the last sample (LNCaP PI15 miR-32 3) is missing because of a pipetting error. B The missing 
replicate from transfection (PC-3 ctrl 3) is due to low concentration of RNA from the extraction. 
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Figure 6. PI15 expression in the mRNA level in co-transfected LNCaP cells, second experiment. There 
were three replicates in transfection (denoted with numbers) A Error bars ± standard deviation from the qRT-
PCR replicates. Sample LNCaP PI15 miR-32 3 was omitted because of pipetting errors in qRT-PCR. B Same 
chart with relative miR-32 expression as determined with TaqMan assay. There were no qRT-PCR replicates 
for the TaqMan assay so the error bars could not be calculated.  
We also tried to detect PI15 expression in the protein level by using both cell lysates and growth 
medium samples extracted from cells transfected both transiently (with pCMV6-XL4 PI15) and 
stably (with pcDNA3.1(+) PI15 ORF) and with two different primary antibodies (rabbit-polyclonal 
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and mouse monoclonal antibody).  Unfortunately, PI15 was not detected in any experiment. There 
were bright bands of proteins both bigger (45 and 75 kDa) and smaller (15 kDa) than PI15. There 
were also some dim bands near the 25 kDa, which is the size of PI15, but they were consistently as 
dim or even dimmer in the samples transfected with PI15 than in the controls. The two antibodies 
detected different unspecific proteins with the brightest bands above 70 kDa for the monoclonal 
antibody and below 15 kDa for the polyclonal. 
 
5.5 Morphology, growth rate and cell viability of stable PI15 clones 
To study the effects of PI15 overexpression on PCa cell lines, stably PI15 expressing cell lines were 
grown by transfecting PC-3 and LNCaP cells with the pcDNA3.1 (+) PI15 ORF vector. Both cell 
lines were grown under antibiotic (Geneticin) selection. However, only PC-3 cells survived the 
selection and thus, growth rate and cell viability was measured from that cell line only. Four different 
clones of PC-3 cells and two control clones transfected with empty vector were used for the assays. 
The overexpression of the PC-3 clones was assessed at the mRNA level with qRT-PCR (Figure 7). 
For this qRT-PCR measurement there was no empty vector transfected controls available so WT 
controls were used as a comparison.  
 
Because there were only two replicates in the qRT-PCR and no error was noticed during the pipetting, 
some of the samples, namely 6000- and 300-fold PI15 overexpression clones, have very high standard 
deviations. These clones throughout the results and in the Appendix Figures will therefore be marked 
with an asterisk (*) after their names. In both cases the erroneous pipetting or other error occurred in 
the PI15 qRT-PCR experiment. Although the standard deviation is large, in each case both of the 
replicates indicated high overexpression. For the 6000-fold overexpression clone the overexpression 
is 2000–17 000-fold and for the 300-fold overexpression clone 60–1350-fold, if calculated with the 
raw data of individual replicates of the PI15 experiment normalized with the averages of the 
housekeeping genes’ data. 
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Figure 7. PI15 expression of the stable PC-3 clones. Error bars ± s.ds. The labels indicate rounded up fold 
changes compared to the PC-3 wild type controls. *The CT values of the qRT-PCR replicates of these samples 
in the PI15 experiment were very far from each other so the s.ds. (error bars) became high. The relative 
expressions of PI15 were calculated by the comparative CT method with TBP as an internal control gene. 
 
The clones acquired differ in their morphology as assessed by light microscopy (Figure 8). Because 
the first control clone does not look like common round PC-3 in morphology, but instead adheres 
tightly onto the surface and there are lots of dead cells in the culture medium, it was excluded from 
the growth and cell viability analysis. The clone with the highest (6000-fold) overexpression of PI15 
also looks quite different from the other clones in that it too adheres flat on the surface and has 
filopodia like extensions protruding around the cells. The cells also contain small vesicles that are 
mostly absent in the other clones. 
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Figure 8. Image panel of the stable PC-3 PI15 clones. Morphology of each stable clone is shown. Controls 
(top row) are stably transfected with empty vector. Images taken in 10 x magnification with Olympus IX71 
microscope. 
 
Growth of PC-3 PI15 clones was next analyzed. Transfected controls were found to grow in four days 
statistically significantly more slowly than the vector transfected controls (Mann-Whitney U test p < 
0,001) (Figure 9). If individual PI15 overexpressing clones are considered, only 900- and 6000-fold 
overexpression clones grow statistically significantly more slowly than the control clones together  
(Mann-Whitney U test, p < 0,01 and p < 0,001). 
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Figure 9. Growth curves of stable PC-3 PI15 clones. Each clone was seeded in six replicate wells and images 
were taken on days 1, 3 and 4 after seeding. Relative growth is the surface area of day three or day four in 
comparison to area measured on the day one (baseline). Error bars ± s.ds. Cells transfected with PI15 grew 
statistically significantly slower than vector transfected clones as assessed by Mann-Whitney U test for the 
day 4 data (p < 0,001). When analyzed separately, 900 and 6000 x PI15 overexpression clones were the only 
ones to reach the statistical significance with Mann Whitney U test as compared to both vector controls (p < 
0,01 and p < 0,001) respectively. 
  
Figure 10. Cell viability of stable PC-3 PI15 clones. Each clone was seeded into six replicate wells in two 
sets. The samples were collected 1 h and 2 h after addition of the AlamarBlue reagent on days one (set one) 
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and four (set two) after seeding. The values presented in the graph are the fourth day values normalized against 
the first day values (baseline). The viability in both measurements was statistically significantly lower in PI15 
transfected cells in comparison to vector transfected cells (Mann-Whitney U test, p < 0,05). Error bars ± s.ds. 
 
In the data shown in Figure 9, the clones are approximately in the inverse order in growth rate in 
comparison to overexpression level. However, in two preliminary experiments done with the PI15 
clones (without vector transfected controls), the order is not as consistent (see Appendix Figure 1).  
The biggest difference in the preliminary experiments (Appendix Figure 1) was that the 50 x PI15 
overexpression clone grows much more slowly than in the final experiment (Figure 9). Although not 
so clearly, the same trend can be seen also in the Figure 9: The 50-fold overexpression clone is 
growing faster than the 300-fold overexpression clone on day three, but already on day four it starts 
to fall behind.  
 
Throughout the experiments, the 6000-fold overexpression clone grows the slowest. Moreover, in the 
data shown in Figure 9, the clone grows statistically significantly more slowly than any of the other 
PI15 overexpression clone (Mann-Whitney U test, p < 0,01). The growth rate of 900-fold PI15 
overexpression clone was also statistically significantly slower than that of 300- and 50-fold 
overexpression clones (Mann-Whitney U test, p < 0,05 and p < 0,01; respectively). On the other hand, 
the growth speed of vector control 3 over 2 also reached statistical significance (Mann-Whitney U 
test, p < 0,01). 
 
Finally, the cell number was assessed indirectly with the AlamarBlue cell viability reagent (Thermo 
Fisher Scientific) (Figure 10). The assay is based on the rate of the metabolism in the sample (cells 
on the culture vessel), which is directly proportional to the amount of live cells. The cells were seeded 
in six replicates and the samples were collected on the days one and four after the seeding. The 
fluorescence that was measured for the day four samples was normalized against the fluorescence of 
the samples from the day one, so the clones with a high growth rate should appear as highly viable in 
the assay.  
 
Indeed, like in the growth rate analysis, the 6000-fold PI15 overexpression clone has the lowest 
viability and the vector control 3 is the most viable. The other clones fall in between these extremes.  
Measurements with both incubation times agreed that the controls have statistically significantly 
better cell viability than the PI15 overexpression clones (Mann-Whitney U test, p < 0,05 for both 
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measurements). The 6000-fold overexpression clone was less viable than the control clones for both 
incubation times (Mann-Whitney U test, p < 0,001). Other overexpression clones were statistically 
significantly less viable only compared to the vector control 3 (Mann-Whitney U test, p < 0,05 for 
50-fold overexpression clone in 1h measurement and p < 0,01 for all other comparisons). Again, also 
the vector control 3’s viability was statistically significantly higher than vector control 2’s (Mann-
Whitney U test, p < 0,01).  
 
As with the growth rate analysis, there are some differences between the results of different cell 
viability assays as well. In the final experiment, the cell viability of the 50-fold overexpression clone 
is larger than that of the other PI15 overexpressing clones, but in the preliminary experiments, the 
same clone had either same, or lower cell viability than the 300- and 900-fold PI15 overexpression 
clones (see Appendix Figure 2). 
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6. DISCUSSION 
6.1 Context of the results 
Invasiveness to the surrounding tissue and eventually to the circulation and distant sites is the most 
lethal characteristic of cancer. Proteolytic cascades in the extracellular space of tumor tissue are key 
in these processes (Joyce & Pollard 2009, Mason & Joyce 2011). Moreover, the balance between 
renewal and degradation of extracellular matrix is set by the balance of proteases and their inhibitors 
(Kessenbrock et al. 2010). For example, activity of MMPs 2, 7 and 9 is increased during PCa 
progression in SV40 T antigen (a viral oncogene) induced small cell carcinoma of the prostate in 
mice (Littlepage et al. 2010). 
 
This work was motivated by the notion that miR-32, an androgen regulated miRNA that has been 
associated with CRPC (Jalava et al. 2012), might regulate expression of PI15, which encodes 
peptidase inhibitor 15. The hypothesis is that if miR-32 downregulates PI15, the activity of proteases 
increases, leading to enhanced invasion of the tumor cells. 
 
MiR-32 is by far more studied than PI15 and there are several studies stating its overexpression in 
PCa (Volinia et al. 2005, Ambs et al. 2008, Waltering et al. 2011, Jalava et al. 2012, Martens-Uzunova 
et al. 2012, Leite et al. 2013) although there are also studies that have found the opposite (Mahn et al. 
2011). This may be because miR-32 has a role especially in advanced PCa (Jalava et al. 2012, Leite 
et al. 2013) and Mahn et al. used only localized PCas in the part of their analysis which concerned 
miRNA expression in tissues. Currently known miR-32 target genes in PCa include BTG2 and 
BCL2L11, (Jalava et al. 2012, Ambs et al. 2008). The functions of these genes are related most closely 
to apoptotic signaling and no validated target gene of miR-32 is related to the regulation of cellular 
migration or invasion (http://amigo.geneontology.org/amigo/search/annotation; 22.6.2016, Carbon et 
al. 2009). 
 
There are few publications about PI15. Two studies have shown PI15 expression in brain cancer cells. 
It is described as a novel protein with weak trypsin inhibiting activity and it is secreted by human 
glioblastoma cell line T98G (Koshikawa et al. 1996). The study did not state a role for PI15 in the 
carcinogenesis. In the second study PI15 mRNA was also found to be expressed in multiple 
neuroblastoma cell lines (Yamakawa et al. 1998), but again no connection to the carcinogenesis was 
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studied. It was stated though that PI15 has homology with GLIPR1, glioma pathogenesis-related 
protein 1 (Yamakawa et al. 1998) that has proapoptotic effects in prostate cancer cells (Ren et al. 
2004). In addition, more recent mass spectrometric study found that PI15 is secreted from prostate 
and detectable from urine after digital rectal examination among other prostatic exosomal secreted 
proteins (Principe et al. 2013).  Authors report over two-fold signal of PI15 in the urine of low grade 
PCa patients compared to healthy individuals using label free quantification (Principe et al. 2013). 
All this data nevertheless does not give much idea about the role of PI15 in the context of the vast 
network of proteases that are expressed from the human genome and in the prostate tissue. Our work 
with the stably transfected cell lines gives some more information about the physiological effects of 
this gene to the prostate cells. 
 
6.2 Co-transfections with PI15 and pre-miR-32  
We aimed to assess if miR-32 regulates expression of PI15 post transcriptionally. Due to the low 
level of expression of the endogenous PI15 in PCa cell lines 
(http://www.betastasis.com/prostate_cancer/prensner_et_al_2011/gene_expression_barplot/ ; Gene: 
PI15; 21.4.2016; Prensner et al. 2011), this was approached by co-transfecting AR positive LNCaP 
cells and AR negative PC-3 cells with pre-miR-32 and PI15 containing plasmid. These cell lines were 
selected for the study due to their different metastatic backgrounds. PC-3 is originally extracted from 
bone and LNCaP from a lymph node metastasis. LNCaP cells are androgen sensitive, whereas PC-3 
cells are not. 
 
 The co-transfection experiments of this work did not produce conclusive results to say if miR-32 
affects PI15 expression or not and the reasons are diverse. First of all, the transient transfection we 
used to assess these effects led to high variation in the transfection outcome. This can be seen from 
Figures 5 and 6 as replicates from transfection show high variation in the expression levels of PI15 
(Figure 5 and 6A) and miR-32 (Figure 6B). The variation in the expression levels could result from 
variation in transfection efficiency (Hollon et al. 1989). Gene dosages in some cells may be very high 
and in others very low. In the optimal situation it would have been useful to assess the transfection 
efficiency, but it was not possible due to the schedule and lack of suitable marker plasmid. It is also 
possible that the transfected agents have not been evenly distributed into all cells. In this case the 
effect of miRNA could be masked by the high PI15 expression in the cells, which have acquired more 
plasmid in comparison to miRNA from the transfection.  
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The problem would have been partially solved also by stable transfection. However, because the 
plasmid we used did not contain selection marker compatible with mammalian cells, stable 
transfection would have needed co-transfection with additional plasmid with the selection marker or 
cloning of the whole PI15 gene to a different plasmid. The former technique is not optimal as it 
produces low level of positive clones. We did not try to clone the whole gene to the pcDNA3.1(+) 
either, because the ORF was better suited for the PI15 overexpression experiments (this will be 
discussed in more detail below). Moreover, the transient co-transfections of pre-miR and target gene 
containing vector have successfully provided consistent results at least with luciferase reporter assays 
in our group (Jalava et al. 2012, Kaukoniemi et al. 2015) and in other groups (Ambs et al. 2008, 
Noonan et al. 2009, Saini et al. 2011). Also due to the schedule of the project, transient transfection 
was a more feasible method. Otherwise it might have been reasonable to subclone the whole gene 
and generate stable cell lines for these experiments as well, although a plasmid with a long gene might 
be more challenging to get transfected. 
 
There might be biological explanations for the modest success as well. If miR-32 binding to PI15 
3’UTR is weak and thus the overall effect on PI15 expression is mild, the change in PI15 expression 
is hard to detect given the high variation in the expression of PI15 resulting from transfection.  
Moreover, some miRNAs downregulate expression of their target genes mostly by translational 
repression, and possibly stabilize the targets (Ambs et al. 2008, Muddasheddy et al. 2011). If miR-32 
binds and represses PI15 without causing degradation of the mRNA, the stable transfection without 
protein level information would have been insufficient for conclusion. 
 
6.3 qRT-PCR experiments 
qRT-PCR experiments of this work demonstrated that the used PI15 plasmids pCMV6-XL4 PI15 and 
pcDNA3.1(+) PI15 ORF were working fine as the cDNA prepared from RNA of untransfected control 
cells or cells transfected with empty plasmid did not present nearly as high signals in the SYBR green 
based experiments. 
 
Mostly the experiments with qRT-PCR were technically successful and the expression levels could 
be determined. However, there was whole PC-3 series (from the second co-transfection experiment) 
of which qRT-PCR results could not be used as all three replicates from transfection (PC-3 PI15 miR-
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32) had too high variation between the two qRT-PCR replicates presumably due to inaccurate 
pipetting or adequate mixing of the samples. In this case the experiment would have benefited from 
more replicates of each sample. Same was evident with the stable PI15 overexpressing clones (Figure 
7) some of which had lot of variation between the samples. In addition, in those co-transfection 
experiments that could be analyzed there were single samples from transfection that were excluded 
from the analysis because of high standard deviation between qRT-PCR-replicates. 
 
In addition, the TaqMan experiment was not fully successful as there was not enough signal from the 
samples of the first co-transfection experiment. The reason for this could be the overall lower yields 
of RNA from the first experiment in comparison to the second round. In addition, it would have been 
preferable to have replicates for this experiment as well. Now there is a chance of unnoticeable 
pipetting errors in the data despite careful pipetting. 
 
6.4 Western blot 
Despite continued efforts, there was no success in the WB experiments. The most probable reason 
for this is that neither of the antibodies we tried in PI15 detection did not bind the protein properly. 
PI15 is not much studied, as discussed previously, and thus there are no literature where to look for 
the best available antibodies for PI15. Both of the antibody suppliers, Origene technologies for the 
rabbit polyclonal antibody and Abnova Corporation for the mouse monoclonal antibody, have used 
synthetic peptides with partial sequences of PI15 as immunogens. It may be that the mature PI15 does 
not have the epitopes in the same conformation as they are in those peptide. In this case it would not 
be surprising that the protein is not identified correctly. 
 
Other less important reasons for the lack of success in the WB experiments are the possible 
inaccuracies of protein concentration measurement due to use of too concentrated standards in some 
instances. This has affected to the amount of protein pipetted into the SDS-PAGE gel. However, it 
does not explain why the PI15 was not detected at all, whereas there were bands marking other 
proteins from every experiment. If new experiments with a working antibody were made, new protein 
concentration measurements should still be made. Additionally, measurements with a house keeping 
gene as an internal control for quantifying the actual expression levels in each sample could be added. 
Yet another means to try to improve the experiment would be to concentrate the collected culture 
medium to have more protein to detect. 
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We cannot exclude the possibility that despite that the transcription was working (as assessed by qRT-
PCR) translation was somehow obstructed. However, the constructs had intact Kozak sequences 
(Kozak 1987) and both expression vectors are well tested with other genes so there should not be 
anything wrong with the sequences. Thus, this possibility seems unlikely. 
 
6.5 Stable cell lines 
Transient transfection is not optimal way to study the effects of gene of interest. In transient 
transfection the vectors are unevenly distributed into the cell population and hence the observed 
effects are not consistent throughout the cell culture. For this reason, stable transfection is used when 
more consistent results are needed. 
 
The establishment of cell lines with stable PI15 expression required subcloning of the PI15 gene to a 
selection marker containing plasmid. We decided to clone PI15 ORF because it is shorter sequence 
and thus, easier to transfect stably and contains no regulatory sequences like miRNA binding sites 
that might interfere with the desired overexpression. Subcloning of the gene was successful and the 
right clones were achieved already from the first transformation as confirmed by Sanger sequencing.  
 
Selection of stably transfected cells was a half success. Although the viable PC-3 clones were 
plentiful, none of the LNCaP clones survived the antibiotic pressure, so those cells would probably 
have benefited for optimization of the old selection protocol with previously determined antibiotic 
concentrations. The consequent lack of point of comparison for the PC-3 cells is unfortunate for the 
results we gained with that cell line. 
 
The results on simple microscopy, growth rate analysis and the cell viability assay give some reason 
to believe that PI15 has an effect to the biology of the PC-3 cell line. The 6000-fold PI15 
overexpression clone presented significantly different phenotype from common PC-3, which usually 
have round shape with some extensions required for migration. The cells (Figure 8, PC-3, 6000 x 
PI15 overexpression) were adhering to the surface of the culture vessel and presented sharp edged 
protrusions as well as small granular structures, possibly resulting from high burden to the exocytose 
machinery of these cells. The cells also had reduced cell viability (Figure 10) and consistently lower 
growth rate (Figure 9) in comparison to all other clones. 
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It needs to be stated though, that to have an effect on biology of the cells the overexpression needs to 
be quite substantial. This is indicated by two observations. Firstly, the clones with more moderate 
overexpression of PI15 have not strictly consistent order in growth rate and cell viability assays as 
can be seen from the preliminary experiments shown in the Appendix Figures 1 and 2. Secondly, the 
effect on cell morphology is restricted to the clone with the most prominent PI15 overexpression. 
 
The fact that the control 2 is in the same level with the 50- and 300-fold overexpression clones in 
growth rate and in the level with 900-fold overexpression clone in the cell viability also show that the 
effects can be caused by changes that are not restricted to the PI15 expression. We did not detect PI15 
in the protein level, which leaves open the possibility that the effects seen are not related to the PI15. 
Thus, further work with the protein detection is needed before it can be stated that PI15 protein is 
causing the observed effects. 
 
6.6 Subcloning of Luciferase 
The luciferase reporter assay is the conventional way to study if a miRNA regulates its target by 
binding to the 3’ UTR. Thus, the cloning of the luciferase gene would have been an important part of 
the project even if the co-transfections would have been a total success. The luciferase proved to be 
quite a difficult target to enhance by PCR. There were multiple bands close to each other in size in 
the gel after agarose gel electrophoresis and for this reason the right product was difficult to purify 
and the yield of the product was low and probably still contained some unspecific product in it. 
Probably due to these reasons cloning was not successful by the traditional restriction–ligation 
method. Hence, we used TOPO-TA cloning.  
 
The gene was amplified with Maxima HS Tac polymerase enzyme, but luckily this polymerase 
proved to be more specific than the originally used HS-Phusion polymerase and there were much less 
unspecific products in the agarose gel. The reason for this might be a contamination in the Phusion 
polymerase tube. The reaction of the TOPO-TA based technique is more efficient than T4 DNA ligase 
because of the differences in the reaction mechanisms of the enzymes. Positive colonies of the 
luciferase construct with the PstI restriction site were acquired on the first attempt of TOPO-TA 
cloning. The construct with the HpaI site however was much too short in agarose gel and the lane 
contained additional ~250 bp product indicating that there may have been some unspecific star 
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activity during the 1h restriction, although a double digestion protocol suggested by the reagent 
manufacturer (Thermo Fisher Scientific) was used. 
 
The Luc2P gene was still subcloned from the pCR-XL-TOPO vector to the pCMV6-XL4 PI15 vector. 
This was done by the traditional cloning, but this time the luciferase gene with the required restriction 
site could be amplified in bacteria and enough specific product was easier to purify from the gel after 
restriction. This made the yield much better than before and the ligation with the T4 DNA ligase was 
successful. It is possible that restriction and ligation of the Maxima HS Tac amplified product itself 
would have provided the same result without the additional TOPO-TA cloning step. 
 
Possibly due to the use of non-proofreading Taq polymerase, a mutation occurred in the during 
cloning. We cannot exclude the possibility that the mutation was in the original pHIV luciferase 
vector as it was not sequenced prior use. Regardless of the source, the mutation affects the amino acid 
sequence of the protein and is not present in the sequences deposited to NCBI GenBank database. 
The mutation site is in the surface of the protein in PDB structure 4g36 (Sundlov et al. 2012) and the 
affected lysine 142 residue is next to another lysine 141. Because the change into glutamic acid 
balances the charge in this part of the protein surface it possibly stabilizes the enzyme. Whether this 
is the case or not may be clarified in the future experiments with the reporter vector construct.  
 
6.7  Future perspectives 
Indeed, to assess the miR-32 PI15 interaction further, the best options to continue would be to try the 
reporter assay with a non-regulated control gene (R. reniformis lusiferase) as a normalizer. Luciferase 
assay measures the changes directly in the protein level as luciferase activity and thus fluorescence 
intensity in the presence of a substrate is directly proportional to the expression of the gene. This 
would bypass the possible problem of mRNA stabilization upon miRNA binding. In addition, the 
internal control gene would allow to assess transfection efficacy, which could not be done by the 
present experiments.  
 
Another strategy to assess the regulatory role of miR-32 would be to simply use some other non-
prostate cell line with higher levels of endogenous PI15 expression. The problem is that the gene is 
not well characterized so the data especially of the protein level expression is scarce. However, there 
are some possibilities. For example, melanoma cell line SK-MEL-30 expresses the gene in mRNA 
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level according to Protein Atlas database (http://www.proteinatlas.org/ENSG00000137558-
PI15/cell/SK-MEL-30; 24.5.2016). If downregulation of luciferase activity or PI15 expression is 
detected with either experiment, the exact binding site should be also identified. This would be done 
by mutating the putative miR-32 binding site with site-directed mutagenesis, for example by 
QuickChange, and measuring the luciferase activity or PI15 expression after new transfection 
experiment. 
 
With the stable PI15 overexpressing clones we should also continue by testing their migration and 
invasion capabilities in wound healing and basement membrane invasion assays respectively to test 
the latter part of our hypothesis, which states that PI15 decreases these abilities. Nevertheless, 
detection of protein PI15 and assessing its overexpression in protein level would be the top priority 
for the future work concentrating to the biological effects of PI15. Also further characterization of 
the PI15 would come into question. As PI15 is not alone responsible for any physiological effects  
that we know of, but instead inhibits function of peptidases, it would be really important to know 
which these enzymes exactly were and what are their roles in the maintenance of tissue homeostasis.   
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7. CONCLUSION 
In this work, we aimed to assess whether PI15 is target of miR-32. This was studied by co-transfecting 
PC-3 and LNCaP prostate cancer cells transiently with these genes and analyzing changes in PI15 
expression by qRT-PCR. Despite the efforts, we did not achieve conclusive results for the matter and 
further research is needed on the subject. 
 
In addition, luciferase reporter vector containing PI15 3’ UTR was constructed to further investigate 
the relationship of PI15 and miR-32. The cloning proved to be challenging due to which the project 
time run out before luciferase reporter assays could be conducted. The subcloning of the reporter 
vector was, however, completed and is available for future studies. The luciferase reporter 
experiments might be a more robust way to assess effects of miR-32 to PI15 expression. This is 
because the luciferase reporter assay measures changes directly in the protein level, whereas the data 
so far was gained on the mRNA level. 
 
We also studied the effects of PI15 overexpression to the PC-3 cells. For this purpose, PI15 ORF was 
successfully subcloned to a vector with a selection marker gene for mammalian cells. With this vector, 
stable PI15 expressing clones were selected for growth rate and cell viability analysis. High 
overexpression of PI15 was found to slow down growth of the PC-3 cell line, and to reduce viability 
of these cells. Interestingly, the high overexpression also resulted into significant phenotypic changes 
in these cells: the cells became more adherent and contained small granules probably due to 
exocytotic processes. In the future, it would be really interesting to see how these changes affect to 
migration and invasion capabilities of these cells. 
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9. APPENDIX 
 
Appendix 1. Growth curve of stable PC-3 PI15 clones. Each clone was seeded in six replicate wells. Relative 
growth is the surface area of day three or day four in comparison to area measured on the day one (baseline).  
Error bars ± s.ds. A and B results are from different experiments. † No PI15 overexpression clone is transfected 
with PI15 plasmid but does not overexpress PI15 as assessed by qRT-PCR. 
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Appendix 2. Cell viability of stable PC-3 PI15 clones. Each clone was seeded in six replicate wells. The 
samples were collected on days one and four after seeding. Samples colleccted 1 h after addition of the reagent 
are shown with blue bars and the ones collected after 2 h are shown in orange. The values presented in the 
graph are the fourth day values normalized against the first day values (baseline).  Error bars ± s.ds. A and B 
are results from different experiments. † The first clone is a stable clone transfected with PI15 plasmid, but 
does not express PI15 compared to WT controls as assessed by qRT-PCR. 
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